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1Parkinson’s disease
Parkinson’s disease is a progressive neurodegenerative disorder that was first described 
by James Parkinson in 1817 in his Essay on the Shaking Palsy [1]. He reported on six 
patients (three of whom he had merely encountered in the street) who had tremor, 
gait disorder and reduced speed of moving. To date the diagnosis of Parkinson’s 
disease is based on the UK Brain Bank criteria [2] and requires the presence of motor 
symptoms such as bradykinesia, rigidity, postural instability and tremor (box 1) [3]. 
These symptoms are primarily the result of the degeneration of dopaminergic neurons 
in the substantia nigra pars compacta [4]. The damage in this brain area affects the 
nigrostriatal pathways whose neurons project onto the striatum, a part of the basal 
ganglia. The cause of the nigral cell death is poorly understood. Besides the damage to 
this specific region, brain areas outside the basal ganglia and other neurotransmitters 
systems are also affected, resulting in a broad spectrum of symptoms and signs [5]. 
Parkinson’s patients do not only present with problems with movement, but they 
can also experience a wide range of non-motor symptoms, such as cognitive 
impairment, psychiatric and behavioural problems, sleep disorders and autonomic 
dysfunction (box 2) [6]. Cognitive problems in Parkinson’s patients are expressed 
as impaired frontal lobe functions such as problems with attention, planning and 
working memory [7]. Psychiatric and behavioral complications include disorders 
of mood such as depression and anxiety [8]. Also impulse control disorders and 
compulsive behavior such as gambling and hypersexuality are seen in Parkinson 
disease [9]. These problems are often caused by the use of dopaminergic medi-
cation [10]. All common sleep disorders can be found in Parkinson’s patients [11]. 
However, some disorders are particularly prevalent in this patient group [12, 13]. 
These will be discussed in more detail in the “sleep and Parkinson’s disease” sec-
tion. The autonomic nervous system is impaired in Parkinson’s disease. Some of the 
autonomic symptoms can be found even years before the onset of motor symptoms 
[14]. Taken together, Parkinson’s disease is a very disabling and complex condition, 
with a heterogeneous presentation.
The estimated prevalence rate of Parkinson’s disease above the age of 60 is 1-1.5% 
[15], and the risk of developing the disease increases markedly with advancing age. 
Parkinson’s disease is still an incurable and progressive disease, but treatment with 
dopaminergic drugs (in particular levodopa or dopamine agonists) can provide a 
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drastic relief of the motor and – to a lesser extent – non-motor symptoms. However, 
within a few years of starting therapy, the majority of patients begin to notice a ‘wearing-
off’ effect, with severely returning symptoms after a certain time past drug intake [16]. 
The accompanying instabilities in motor function are referred to as motor fluctuations. 
In well-selected patients where pharmacotherapy is becoming a challenge, brain 
surgery (in particular implanting deep brain stimulation electrodes) can be a treatment 
option [17, 18].
The non-motor symptoms, especially the cognitive disturbances, are even more 
difficult to treat than the motor symptoms. This is regretful, because these symptoms 
have been shown to be the main determinant of impaired quality of life in Parkinson’s 
patients [19].
Box 1  |  Motor symptoms of Parkinson’s disease
• Bradykinesia 
Slowness of initiating voluntary movement and sustaining repetitive movement 
with progressive reduction in speed and amplitude 
Accompanied by at least one of the following features:
• Resting tremor 
Involuntary rhythmic oscillatory (4-6 Hz) movement of a body part
• Rigidity 
Increased resistance to passive displacement
• Postural instability 
Poor balance, unsteadiness and falls
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1Box 2  |  Non-motor symptoms of Parkinson’s disease
• Cognitive impairment: 
 · Problems with decision making 
 · Impaired planning and goal directed behaviour.
 · Dementia 
• Psychiatric and behavioural complications: 
 · Hallucinations 
 · Depression 
 · Anxiety 
 · Impulse control disorders 
 · Compulsive behaviours
 · Apathy  
• Sleep disturbances: 
 · Problems with sleep initiation and maintenance 
 · REM sleep behavior disorder 
 · Excessive daytime sleepiness
 · Restless leg syndrome
 · Difficulties turning in bed 
• Autonomic dysfunction: 
 · Orthostatic hypotension 
 · Constipation
 · Urinary dysfunction 
 · Sexual dysfunction 
 · Excessive drooling
Sleep benefit in Parkinson’s disease
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Sleep
Although we spend approximately one third of our life sleeping, only little is known 
about the mechanisms and functions of sleep. Sleep is an universal phenomenon 
across species and can be defined behaviourally by four criteria: 1 | reduced motor 
activity, 2 | decreased response to stimulation, 3 | stereotypic posture (in humans, for 
example, lying down with eyes closed) and 4 |  relatively easy reversibility (distinguishing 
it from coma, hibernation and anaesthesia) [20].
Sleep and its different stages are defined by electrophysiological measures. 
The electroencephalogram (EEG) is used to monitor activity of cortical neurons, 
electromyography (EMG) to measure muscle tone and electro-oculography (EOG) to 
register eye movements. During sleep, two major phases occur: Rapid Eye Movement 
(REM) sleep and non-REM sleep. Besides the rapid eye movements, REM sleep is 
characterized by the complete inhibition of skeletal muscle tone. 
According to the AASM sleep scoring criteria [21], non-REM sleep can be further divided 
into three stages, all accompanied by characteristic changes in the EEG (figure 1). 
Stage 1 is the transition from wakefulness to sleep. Relaxed wakefulness with eyes 
closed is dominated by the alpha rhythm (~8-12 Hz), falling asleep is characterized by 
increased theta (~4-8 Hz) EEG activity. 
Stage 2 can be identified by the presence of sleep spindles (bursts of sinusoidal waves 
(~12-14Hz)) and K-complexes (high voltage biphasic waves) in the EEG. 
Stage 3 EEG is dominated by high amplitude, slow delta waves (~0.5-2 Hz), therefore, 
this stage is also called slow-wave sleep. 
The different stages of non-REM sleep and REM sleep alternate cyclically during 
sleep (figure 2). In human adults, a complete sleep cycle is 90-120 minutes, resulting 
in approximately 4 to 5 cycles per night. In the first half of the night the periods of 
slow wave sleep are relatively long, whereas in the second half of the night this shifts 
towards more REM sleep per cycle. 
1 |  General introduction
15
1Figure 1  |  EEG activity during different sleep stages 
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Functions of sleep
Despite decades of sleep research, the exact functions of sleep are still poorly 
understood. At the body level, sleep is known to be involved in modulating 
endocrine function [22, 23], regulating immune system integrity [24] and controlling 
thermoregulation [25]. At the central brain level, sleep supports neurocognitive 
functions such as learning, memory and brain plasticity [26, 27]. During sleep, complex 
processes take place that play a key role in processing and consolidation of both 
declarative memory and procedural memory. The exact nature of these processes 
is not completely understood, but a few main hypotheses have been proposed. 
According to the synaptic homeostasis hypothesis, the net increase in synaptic 
connections that is made during wakefulness is downscaled during slow wave sleep 
in a way that is efficient for learning and memory [28, 29]. The consolidation model 
proposes a selective reactivation during sleep of the brain areas that were active 
during wakefulness [30, 31]. Sleep dependent learning is shown not only after night 
sleep, but also after daytime naps [32, 33].
Sleep and its complex functions are often studied by depriving subjects from sleep. 
Function impairment after severe sleep loss can be assessed subsequently. However, 
this technique has some drawbacks. The effects of sleep deprivation are broad and 
non-specific and it is not possible to study the influence of specific sleep stages. 
Partial sleep deprivation, where a subject is awakened when entering a specific sleep 
stage, can be used to account for the latter problem. However, this is a difficult and 
Figure 2  |  Schematic hypnogram of sleep stages across the night 
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1labour-intensive option. Alternatively, the beneficial effects of sleep can be studied 
by observing task performance before and after night sleep or a daytime nap. When 
addressing night sleep, also the influence of circadian rhythm effects should be taken 
into account. Naps are less sensitive for these circadian effects and convenient in an 
experimental setting.
Sleep in Parkinson’s disease
Sleep disorders are highly prevalent in Parkinson’s disease. Nocturnal sleep distur-
bances affect 60-98% of patients with Parkinson’s disease [12, 13]. The most common 
complaints in Parkinson’s patients are frequent and prolonged awakenings or sleep 
fragmentation. REM sleep behaviour disorder (RBD), a sleep disorder characterized 
by the occurrence of muscle activity during REM sleep with the manifestation of dream 
enactment, is very common in Parkinson’s patients [34, 35]. Idiopathic RBD is regard-
ed a powerful marker of the pre-motor phase of Parkinson’s disease and other synu-
cleinipathies. Prospective studies have shown that 40-65% of patients with idiopathic 
RBD develop Parkinson’s disease or a related neurodegenerative disorder [35, 36]. 
Some sleep disorders are directly related to striatal dopamine depletion or treatment 
with levodopa, others can be attributed to for example depression or difficulties with 
turning in bed [37]. (Excessive) daytime sleepiness is seen in 20-50% of the patients 
[38]. This results partially from poor overnight sleep, partially from medication use 
(causing drowsiness as adverse effect), but it may also be a direct cause of neurode-
generation of wake promoting areas in the brain.
Intriguingly, sleep might also have beneficial effects in patients with Parkinson’s 
disease. In the clinical literature, there are reports of Parkinson’s patients experiencing 
a reduction in Parkinson’s symptoms after sleep [39-46]. Upon awaking in the morning 
they experience good mobility as if they are in the “on” state, contrary to what would 
be expected after a night without medication. Marsden was the first who described 
this phenomenon and coined the term “sleep benefit” [43]. Some Parkinson’s patients 
are even able to delay or skip their morning dose of medication because of sleep 
benefit [44]. As such, sleep benefit could have great clinical potential, as a “natural” 
symptomatic treatment, alongside more traditional medical management. However, 
the scientific background for sleep benefit is limited, and not all medical practitioners 
are familiar with this phenomenon. 
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Outline of this thesis 
The reported experiences of patients with sleep benefit are fascinating. However, not 
much is known about these beneficial effects of sleep in Parkinson’s disease. In this thesis, 
we set the stage for the intriguing, but elusive phenomenon of sleep benefit, that has not 
been studied for more than a decade. We aimed to study sleep benefit thoroughly, from 
several perspectives and by employing diverse methodological approaches. 
In chapter 2 we assess the prevalence of sleep benefit in a large sample of Parkinson’s 
patients from our clinic, showing that sleep benefit deserves renewed attention and 
further research.
In chapter 3 we provide a systematic review of the current literature on sleep benefit 
in Parkinson’s disease, including the data presented in chapter 2. We discuss the 
prevalence, clinical effects and determinants of the phenomenon. We interpret these 
findings, with special emphasis on the definition of sleep benefit and the possible 
mechanisms underlying sleep benefit. We also address the potential clinical application 
as a novel symptomatic intervention. Finally, we propose a new definition of sleep 
benefit to allow for improved standardization and homogeneity in future research. 
Most research on sleep benefit has been performed with retrospective question-
naires. In chapter 4, we address this issue, by describing a study where we developed 
a tailored symptom diary in which patients could prospectively report an indication of 
specific motor functioning before and directly after every period of sleep. This way, we 
obtained sleep-related changes in subjective motor functioning over multiple days, 
without explicitly asking patients about the phenomenon of sleep benefit. This chapter 
presents the results of the diaries and compares these with a retrospective question-
naire which was completed by the patients afterwards.
Since studies using objective measures of sleep benefit are limited, we designed 
a study using quantitative measures of motor function before and after sleep. In 
chapter 5 we compare and describe sleep-related changes in motor function among 
patients who reported having experienced sleep benefit, among those who had 
not and among healthy elderly controls. We focus not only on nighttime sleep, but 
also on daytime naps. The quality and characteristics of sleep is assessed using 
polysomnography and subjective ratings of motor function and mood/vigilance are 
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1obtained, to examine whether these are related to changes in motor functioning.
Chapter 6 is dedicated to the clinical exploration of subjective sleep benefit. Using 
qualitative research methods based on the grounded theory framework, we aim to 
get more insight in what patients, who report sleep benefit, experience when they 
wake up. Furthermore, our objective is to identify the factors that may influence the 
self-reported sleep benefit.
In chapter 7 we present a study design for future research on sleep benefit. Specifically, 
we describe a new technique for computerized vision based (video) analyses that can 
be used to assess motor performance upon awakening in a home environment. With 
this technique spatiotemporal and kinematic data (such as walking speed, joint angles, 
step length, arm swing etc) can be automatically extracted from the video registration. 
This allows for longitudinal objective assessment of daily life movements without 
having to wear sensors.
In chapter 8 the main findings are discussed and directions and challenges for future 
research are evaluated. Finally, chapter 9 summarizes this thesis.
Sleep benefit in Parkinson’s disease
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Abstract
Some patients with Parkinson’s disease reportedly experience ‘sleep benefit’: an 
improved motor functioning upon awaking in the morning. In this questionnaire study, 
114 out of 243 consecutive outpatients with Parkinson’s Disease (46.9%) subjectively 
experienced sleep benefit. Among those patients that regularly took an afternoon 
nap, 33.7% experienced sleep benefit after the nap as well. Between patients with and 
without sleep benefit, there were no differences in demographic or clinical variables, 
including age, disease duration, dopaminergic treatment, and nocturnal sleep quality. 
Sleep benefit remains an intriguing but elusive phenomenon, which deserves renewed 
attention and further research. 
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Introduction 
Some patients with Parkinson’s disease report a beneficial effect of sleep, with an 
improved motor functioning upon awaking in the morning, contrary to what would 
be expected after a night without medication. This intriguing phenomenon is known 
as sleep benefit [1]. The prevalence of sleep benefit seems relatively high. In previous 
studies, about 45% of patients report that they experience sleep benefit in the morning 
[2-6]. Sleep benefit has been primarily studied in the context of nocturnal sleep, but 
there are reports that it occurs after daytime naps as well [5-7].
It remains unknown why some Parkinson’s patients do experience sleep benefit and 
others do not. In various studies possible determinants of sleep benefit were assessed, 
including age, age at onset, disease duration and presence of motor fluctuations [2-6]. 
However, results varied widely and no consistent sleep benefit-associated variables 
have been found to date.
In the present study, we assessed a large sample of Parkinson’s patients, focussing 
on two aspects of sleep benefit. First, we estimated the prevalence of sleep benefit 
not only after nighttime sleep, but after daytime naps as well. In addition, we studied 
possible determinants, comparing clinical characteristics of patients reporting sleep 
benefit versus patients not familiar with the phenomenon.
Methods 
Subjects
We studied 253 consecutive Parkinson’s patients visiting the Parkinson Centre 
Nijmegen (ParC), a tertiary referral centre. All subjects fulfilled the clinical criteria for 
idiopathic Parkinson’s disease. The study was performed according to the guidelines 
of the Medical Ethical Committee of the Radboud University Nijmegen Medical Centre. 
All patients provided written informed consent to participate. 
Clinical characteristics 
Demographic and disease-related characteristics such as age and years on 
dopaminergic treatment were taken from the clinical chart. Age at onset was defined 
as the onset of motor symptoms deduced from the clinical interview. Disease severity 
Sleep benefit in Parkinson’s disease
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was rated using the Hoehn and Yahr (H&Y) staging system [8]. Dopaminergic 
treatment was quantified by calculating the Levodopa Equivalent Dose (LED) [9].
Questionnaires
Before their initial visit to the Parkinson Centre, patients completed a comprehensive 
clinical screening questionnaire covering the range of motor and non-motor symptoms 
occurring in Parkinson’s disease. Depressive symptoms were rated using the Beck’s 
Depression Inventory (BDI) [10]. As an overall indicator of functioning and quality of life, 
the Parkinson’s Disease Quality of Life questionnaire (PDQL) was used [11]. 
We defined sleep benefit as “a clear decrease in Parkinson’s symptoms after a period 
of sleep”. Patients had to indicate whether or not they experience such a decrease in 
symptoms after a period of sleep, either nocturnal sleep or daytime naps. Patients giving 
a positive answer to at least one of the conditions were classified as having sleep benefit.
Nocturnal sleep quality was rated using the Pittsburgh Sleep Quality Index (PSQI) [12]. 
Daytime sleep habits were scored based on the frequency of naps, choosing between: 
never, incidentally, often or always. Patients indicating often or always were classified 
as regular nappers. The presence of excessive daytime sleepiness was rated using the 
Epworth Sleepiness Scale [13]. 
Analyses
Statistical analyses were performed using SPSS for Windows (version 18), with chi-
square tests and t-tests depending on the variable. Missing data was <10% for all 
variables (except duration of dopaminergic treatment; 16%), so outcomes are presented 
as valid percentages. 
Results 
In 10 patients, data on the presence of sleep benefit was incomplete. Therefore, 
243 patients (147 men) were included in the analyses. A total of 114 patients (46.9%) 
indicated to experience sleep benefit. The demographic and clinical characteristics of 
both groups can be found in Table 1. Between patients with and without sleep benefit, 
there were no differences in demographic or clinical variables, including age, age at 
onset, disease duration and dopaminergic treatment. Also, there were no differences 
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in depression, quality of life scores, or PDQL items rating memory, fatigue and apathy. 
In addition, there were no discriminating differences in sleep quality, as assessed by 
total PSQI scores, or the seven PSQI subscales [12]. 
Table 1  |  Demographic, clinical and sleep characteristics
SB No SB p
N 114 129
Men (%) 66 (57.9%) 81 (62.6%) 0.436
Age (yr) 64.78 ± 9.992 64.78 ± 9.122 0.999
Age at PD onset (yr) 56.61 ± 10.59 56.92 ± 10.49 0.823
Duration of symptoms (yr) 8.07 ± 5.72 7.86 ± 6.01 0.790
Duration of dopaminergics use (yr) 6.97 ± 5.57 6.65 ± 6.12 0.701
Levodopa Equivalent Dose (mg/day) 512 ± 407 452 ± 362 0.226
Use of dopamine agonists (%) 52 (45.6%) 53 (41.1%) 0.477
Hoehn & Yahr stage 0.516
 1 / 1.5 11 (10.3%) 16 (13%)
 2 / 2.5 65 (60.8%) 78 (63.4%)
 3 26 (24.3%) 21 (17.1%)
 4 / 5 5 (4.7) 8 (6.5%)
PDQL 88.77 ± 22.21 90.16 ± 23.22 0.637
Beck’s Depression Inventory 10.54 ± 6.376 10.91 ± 6.52 0.662
Pittsburgh Sleep Quality Index score 7.28 ± 3.99 6.79 ± 3.87 0.333
 Total sleep duration (hrs) 6.69 ± 1.53 6.86 ± 1.70 0.429
 Sleep efficiency (%) 80.32 ± 16.34 83.73 ± 15.83 0.106
Epworth Sleepiness Scale 6.66 ± 4.90 6.69 ± 4.79 0.965
PDQL | Parkinson’s Disease Quality of Life questionnaire, SB | sleep benefit 
Results are shown as N (%) or mean ± SD. 
Data are presented as valid percentages. 
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Regular daytime naps were taken by 98 patients (40.8%). Data on sleep benefit in 
relation to daytime naps are summarized in Table 2. There was no significant difference 
in prevalence of sleep benefit between regular nappers and non-regular nappers 
(X2 = 3.256, p = 0.071), however, patients who napped on a regular base obviously 
experienced sleep benefit after a nap more often. Of the regular nappers, 20 patients 
(20.4%) reported sleep benefit after both nocturnal sleep and naps, and 20 patients 
only after nocturnal sleep. Thirteen patients (13.3%) reported to experience sleep 
benefit only after a daytime nap. The PSQI scores of these patients did not differ from 
other patients who regularly took a nap (t = 0.314, p = 0,754).
Table 2  |  Naps and Sleep Benefit 
No SB SB 
only after 
night sleep
SB 
only 
after nap
SB after
both night 
sleep and nap
Total
Non-regular nappers 82 (57.7%) 45 (31.7%) 2 (1.4%) 13 (9.2%) 142
Regular nappers 45 (45.9%) 20 (20.4%) 13 (13.3%) 20 (20.4%) 98
Total 127 (52.9%) 65 (27.1%) 15 (6.8%) 33 (13.8%) 2401
SB | sleep benefit
Results are shown as N (%). 1 Nap data missing in 3 patients.
Discussion 
In this study, we confirm that almost half of the patients with Parkinson’s disease (46.9%) 
experience a subjective decrease in symptoms after sleep. This prevalence number is 
fairly consistent across studies so far [2-7]. Furthermore, sleep benefit is not limited to 
nocturnal sleep. We found that in patients who regularly take naps, 33.7% experiences 
sleep benefit after daytime sleep. The presence of sleep benefit after daytime sleep 
was not related to the quality of nighttime sleep. It is tempting to speculate whether 
daytime naps might constitute a possible therapeutic application, e.g. for patients with 
medication-related motor fluctuations. 
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The fact that about half of Parkinson’s patients report subjective sleep benefit – 
whereas the other half does not – remains interesting. Several studies have addressed 
a range of possible clinical determinants in relation to sleep benefit, but found varying 
results. For example, some have found that sleep benefit was related to earlier 
age of onset, longer disease duration, longer medication use or more fluctuations, 
but others could not confirm these findings [2-7]. In our analysis of a large sample 
of Parkinson’s patients, the presence of sleep benefit could not be associated with 
specific demographic or clinical factors. There was no association with disease stage, 
although the Hoehn and Yahr may lack sensitivity in this respect. We used the PSQI 
and ESS as measures for nocturnal sleep quality and daytime sleepiness respectively. 
The experience with these questionnaires is extensive, but validation in Parkinson’s 
disease is limited. However, this is also true for sleep scales that have recently been 
specifically developed for Parkinson’s diease.
It is important to realize that the considerable variation in outcomes of studies assess-
ing possible determinants of sleep benefit can in part be explained by the application 
of different definitions of sleep benefit. Both our results and most preceding studies are 
based on the subjective patient judgment on the presence of sleep benefit. This is an 
important limitation, as current definitions of sleep benefit may be susceptible for mis-
interpretation. For example, sleep benefit could be confused with a-specific feelings of 
refreshment after sleep. Moreover, little is known about the relation between subjec-
tive experience and objective motor performance. Only one study assessed objective 
motor functioning before and after sleep, using the motor part of the Unified Parkin-
son’s Disease Rating Scale (UPDRS) [14]. There was a small but significant difference in 
UPDRS change after sleep in patients with and without subjective sleep benefit. How-
ever, the authors report considerable discrepancies between subjective and objective 
outcomes. Patients with subjective sleep benefit described their morning state as “the 
best moment of the day” while their UPDRS scores were indicative of being in the “off” 
state, and the morning dose of levodopa still improved motor functioning.
In future studies, it will be of major importance to use objective quantifications in motor 
performance for the diagnosis of sleep benefit. In addition, subjective scoring of sleep 
benefit could be improved with longitudinal assessment of Parkinson’s symptoms, 
using actigraphy, sleep diaries or pre and post-sleep measures during several days. 
If sleep benefit is rated based on a retrospective patient report, it is essential that a 
standardized and unambiguous definition of sleep benefit is provided. 
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No formal studies into the underlying mechanisms of sleep benefit have been 
conducted so far. Several hypotheses have been proposed. Sleep benefit has been 
attributed to improved dopaminergic function as a result of increased dopamine 
storage in nigral neuronal terminals during sleep [2, 5, 6]. It has also been proposed 
that sleep benefit could be unrelated to sleep, and merely represents a “morning 
benefit” related to the time of awakening and pattern of motor fluctuations [4]. The 
occurrence of sleep benefit after daytime naps suggests a specific role for sleep 
however. Future studies should collect data on nap timing, duration and frequency, 
in order to exclude a possible relation with a (circadian) pattern of motor fluctuations. 
Studying the possible presence of sleep benefit in neurodegenerative disorders other 
than Parkinson’s disease, such as Lewy body dementia or episodic ataxia [15], might 
also lead to new insights in the mechanisms underlying sleep benefit.
Sleep benefit remains a fascinating, but mysterious phenomenon. If the subjective 
experience of sleep benefit is proven to be related to an objective improvement in 
motor function, this could have considerable clinical benefits. In addition, it will be 
important to further study possible determinants and underlying mechanisms of 
sleep benefit, in order to identify those patients most likely to benefit from sleep. Given 
the promising results as well as the unresolved questions on sleep benefit, the paucity 
in sleep benefit-related research over the last decade is remarkable. Both our data and 
previous studies show the importance to renew research on this intriguing subject.
33
References 
1 | Marsden CD: “On-off” phenomena in Parkinson’s disease. In Parkinson’s disease: current 
progress, problems and management. Edited by Rinne U, Klinger M, Stamm G. Amsterdam: 
Elsevier; 1980: 241-254
2 | Bateman DE, Levett K, Marsden CD: Sleep benefit in Parkinson’s disease. Journal of 
neurology, neurosurgery, and psychiatry 1999, 67:384-385.
3 | Currie LJ, Bennett JP, Jr., Harrison MB, Trugman JM, Wooten GF: Clinical correlates of 
sleep benefit in Parkinson’s disease. Neurology 1997, 48:1115-1117.
4 | Factor SA, Weiner WJ: ‘Sleep benefit’ in Parkinson’s disease. Neurology 1998, 50:1514-
1515.
5 | Merello M, Hughes A, Colosimo C, Hoffman M, Starkstein S, Leiguarda R: Sleep benefit in 
Parkinson’s disease. Movement disorders : official journal of the Movement Disorder Society 
1997, 12:506-508.
6 | Tandberg E, Larsen JP, Karlsen K: Excessive daytime sleepiness and sleep benefit in 
Parkinson’s disease: a community-based study. Movement disorders : official journal of the 
Movement Disorder Society 1999, 14:922-927.
7 | Pal PK, Thennarasu K, Fleming J, Schulzer M, Brown T, Calne SM: Nocturnal sleep 
disturbances and daytime dysfunction in patients with Parkinson’s disease and in their 
caregivers. Parkinsonism & related disorders 2004, 10:157-168.
8 | Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967, 
17:427-442.
9 | Esselink RA, de Bie RM, de Haan RJ, Lenders MW, Nijssen PC, Staal MJ, Smeding 
HM, Schuurman PR, Bosch DA, Speelman JD: Unilateral pallidotomy versus bilateral 
subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004, 62:201-207.
10 | Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring 
depression. Arch Gen Psychiatry 1961, 4:561-571.
11 | de Boer AG, Wijker W, Speelman JD, de Haes JC: Quality of life in patients with Parkinson’s 
disease: development of a questionnaire. Journal of neurology, neurosurgery, and psychiatry 
1996, 61:70-74.
12 | Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep 
Quality Index: a new instrument for psychiatric practice and research. Psychiatry research 
1989, 28:193-213.
13 | Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness 
scale. Sleep 1991, 14:540-545.
14 | Högl BE, Gomez-Arevalo G, Garcia S, Scipioni O, Rubio M, Blanco M, Gershanik OS: A 
clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson’s 
disease. Neurology 1998, 50:1332-1339.
15 | Nagappa M, Mundlamuri RC, Satishchandra P, Pal PK: Sleep benefit in a case of Episodic 
ataxia. Parkinsonism & related disorders 2011.
2
2 |  References
three
335
three
Published as:
van Gilst, M. M., Bloem, B. R., Overeem, S. 
“Sleep benefit” in Parkinson’s disease: a systematic review. 
Parkinsonism and Related Disorders, 2013 19(7): 654-659. 
A systematic
review on
sleep benefit
in Parkinson’s
disease
Sleep benefit in Parkinson’s disease
36
Abstract
Sleep disorders are common among patients with Parkinson’s disease. However, 
there are also reports of Parkinson’s patients experiencing a beneficial effect of sleep. 
Upon awaking in the morning some patients experience good mobility, as if they are in 
an “on” state induced by medication, contrary to what would be expected after a night 
without medication. This intriguing phenomenon is known as sleep benefit. Here, 
we review the available research on sleep benefit in Parkinson’s disease, describing 
its prevalence, clinical effects and determinants. We also discuss the possible 
mechanisms underlying sleep benefit, and the potential clinical applicability. Finally, 
we propose a new definition of sleep benefit to allow for improved standardization and 
homogeneity in future research. Important research targets include the development 
of objective measures of sleep benefit, as a basis for obtaining a better understanding 
of sleep benefit, its underlying mechanisms and its potential therapeutic application.
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Introduction
Parkinson’s disease remains an incurable and progressive disease. Treatment with 
dopaminergic drugs can provide a impressive relief of the motor symptoms but, within 
a few years of starting treatment, most patients notice an ‘end of dose deterioration’ 
or ‘wearing-off’ effect [1]. On the other hand, high doses of dopaminergic medication 
can induce dyskinesias, which for some patients can be severely disabling [2]. Finding 
the precise balance in treatment is therefore difficult in patients receiving long-term 
treatment. To complicate matters further, non-motor symptoms of Parkinson’s disease, 
such as depression, cognitive decline or sleep disorders, are often under-recognised 
and under-treated [3]. This is unfortunate because these non-motor symptoms largely 
determine the deterioration in quality of life in Parkinson’s disease [4]. Alternative 
treatment strategies would be a valuable addition to the current therapeutic arsenal. 
Here, we discuss how using the beneficial effects of sleep in Parkinson’s disease may 
form the start towards a new treatment option. 
Sleep in Parkinson’s disease
Most often, sleep in Parkinson’s disease is associated with sleep disorders, which affect 
60-98% of Parkinson’s patients [5-7]. However, there are also reports of Parkinson’s 
patients experiencing a beneficial effect of sleep. Upon awaking in the morning 
some patients experience a good mobility, as if they are in the “on” state induced by 
medication, contrary to what would be expected after a night without medication. 
Marsden [8] was the first to describe this phenomenon, labelling it “sleep benefit”. 
Patients with sleep benefit report that when they first get up in the morning, before 
taking any medication, they feel “as under the effect of medication, reasonably active 
and trouble free” or even “this is my best time, as if I had no disease or it were much 
milder” [9]. Some Parkinson’s patients can even delay or skip their morning dose of 
medication because of sleep benefit [9]. These are intriguing observations with great 
potential.
Here, we systematically review the current research on sleep benefit in Parkinson’s 
disease. First, we discuss the prevalence, clinical effects and determinants. We then 
interpret these findings with special emphasis on the definition of sleep benefit, the 
possible mechanisms underlying sleep benefit, and address the potential clinical 
application.
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Methods
We performed a PubMed search for research papers published in English between 
1980 and 2011. We employed a combination of search terms: (“sleep benefit” or 
“diurnal fluctuation”) and (“Parkinson’s disease” or “Parkinsonism” or “hypokinetic 
rigid syndrome” or “extrapyramidal disorder”). In addition, reference lists of identified 
articles were screened for potential other relevant papers. This search yielded six 
experimental studies, all published before 2000 [9-14]. Recently, new data on sleep 
benefit were presented by our group [15]. Here, we also discuss more general papers 
on sleep and sleep disorders in Parkinson’s disease, which mention sleep benefit, 
albeit not as the primary topic [7, 16, 17]. Not all of these latter papers could be retrieved 
using formal search instruments, so this selection may not be complete. Performing a 
meta-analysis of experimental data would be ideal; however, the number of available 
research studies on sleep benefit is limited. Moreover, these studies addressed very 
different questions and hypotheses, and employed different methodologies. These 
issues precluded a formal (meta-)analysis. The current report is therefore a systematic 
review, describing and comparing the available knowledge on sleep benefit. 
Subsequently, we discuss the implications of these findings.
Results
Definition of sleep benefit
The term “sleep benefit” is typically used to describe the phenomenon of Parkinson’s 
patients experiencing an apparently significant improvement in mobility upon awaken-
ing in the morning, before taking the first medication dose. Unfortunately, there is wide 
variability in the descriptions of sleep benefit between the published studies. Table 1 
shows the definitions used in these studies. The definitions varied in several important 
aspects. First and most notable, the definition of the amount of improvement varied, 
ranging from “a clear decrease in Parkinson’s symptoms” to “feeling “on””, to “the best 
time of the day” [9-15]. These definitions were always qualitative and never quantitative. 
Other differences pertained to the specific characteristics of sleep benefit. One group 
stated that sleep benefit could occur after both nighttime and daytime sleep [14], 
whereas others restricted sleep benefit to a morning phenomenon [9, 11-13] or were 
not explicit [10, 15]. Most available studies used questionnaires to assess sleep benefit, 
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and this subjective character was emphasized in some definitions [9, 11-14]. Finally, in 
two studies specific emphasis was put on the temporary character of symptom relief 
caused by sleep benefit [10, 14].
Table 1  |  Definitions of sleep benefit used in different studies
Definition of sleep benefit
Currie et al. 
1999 [11]
“Patient’s stated subjective experience of feeling “on” upon awakening 
from sleep and not in need of morning medication to initiate activities.”
Merello et al. 
1997 [9]
SB was confirmed whenever patients replied affirmatively to all of the 
following:
1 |  Question: “When you first get up in the morning, before you’ve 
taken any medication, how do you feel?” 
Answer: “As if I were under the effect of medication, reasonably 
active and trouble free” or “This is my best time, as if I had no 
disease or it were much milder.”
2 | Question: “Do you have tremor/difficulty in walking/hand clumsiness 
in the morning when you first get up before you’ve taken any 
medication?”  
Answer: “Less than usual” or “I have no tremor/difficulty in walking/
hand clumsiness in the morning.”
3 | Question: “Would you say that sleep during the night benefits the 
symptoms of your Parkinson’s disease in the morning?”
Factor and Weiner 
1998 [12]
“Patients awaken in the morning not only able to initiate activity without 
medication, but claiming that they feel better at that time than at any 
time during the day when receiving medications.”
Hogl et al. 
1999 [13]
“clear-cut subjective motor restoration after a night sleep, self-
perceived mobility in the morning before drug intake appreciated as 
better than during the rest of the day, subjective Parkinson’s symptoms 
clearly reduced or even abolished, and minimum duration ≥ 1 hour.”
Bateman et al.
1999 [10]
“Mobility as good as “on” on awakening, which wears off over a variable 
period.”
Tandberg et al. 
1999 [14]
“A period of lessened disability or feeling “on” on awakening from sleep 
in the morning or after sleeping during daytime.”
Van Gilst et al. 
2012 [15]
“A clear decrease in Parkinson’s symptoms after a period of sleep.”
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Characteristics of sleep benefit
Mainly questionnaires have been used to evaluate the characteristics of sleep benefit. 
Duration of sleep benefit was assessed in two studies [9, 10]. The variation in answers 
was considerable; with duration ranging from 3 up to 300 minutes [9]. In both reports, 
the mean duration was around 80 min [9, 10]. Sleep benefit is most often reported 
to occur after nighttime sleep. However, there are also reports of sleep benefit after 
daytime naps [9, 14, 15, 17]. Sex differences vary: one study reported that sleep benefit 
was more common in men (65%) than women (42%) [9], but others failed to replicate 
this [11, 15]. 
In addition to the use of questionnaires, two studies assessed motor performance, 
using the Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores [10, 13]. 
Although there was no difference in morning function, comparisons between evening 
and morning status showed an improvement in motor function in patients reporting 
sleep benefit, and a deterioration in patients without sleep benefit (both groups N=10) 
[13]. With a mean decrease of 6.5 (sd 8.6) points on the UPDRS motor scale in the 
sleep benefit group and a mean increase of 3.9 (sd 5.9) points in the no-sleep benefit 
group, the differences between the overnight changes were significant (p = 0.019). It 
should be noted however, that there were large interindividual differences in UPDRS 
changes in this study, with a few strikingly large improvements of more than 20 
UPDRS points. In the other study using UPDRS scores, sleep benefit was assumed 
to be present in 6 out of 16 patients based on the UPDRS motor scores [10]. However, 
neither classification criteria nor UPDRS difference scores were provided in the report.
Prevalence of sleep benefit
Most studies assessed the prevalence of sleep benefit after nighttime sleep. Overall, 
prevalence numbers were similar across studies, with a clear dichotomy between 
patients who do experience sleep benefit and patients who do not. Prevalence 
estimates ranged from 33 to 55% of Parkinson’s patients who recognized the 
phenomena, with a mean of 44%. An overview of prevalence rates in the available 
studies can be found in Table 2. 
Sleep benefit can also occur after daytime naps. Merello et al. reported that, 80% of 
patients took afternoon naps and 24.6% of them reported sleep benefit afterwards 
[9]. The frequency of sleep benefit after napping was higher among patients who 
also experienced early-morning sleep benefit (71%) compared to those who did not 
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Table 2  |  Overview of results of different studies on sleep benefit 
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(21%). In a more general study on sleep disturbances in Parkinson’s disease, 42,5% 
of the patients experienced sleep benefit [17]. Of those patients, 57,1% did so after 
both nighttime and daytime sleep, and 21.4% only after nighttime sleep. There were 
also patients who only experienced sleep benefit after a daytime nap (21.4%) [17]. In 
our recent sample, we found no significant difference in prevalence of sleep benefit 
between patients that regularly took a nap and non-regular nappers [15]. Of the regular 
nappers, 20.4% reported sleep benefit after both nighttime sleep and naps, and 20.4% 
of the patients only after nighttime sleep. Thirteen percent of patients experienced 
sleep benefit only after a daytime nap [15].
Determinants
Given the rather striking dichotomy between patients who experience sleep 
benefit and others who do not, a broad range of possible demographic and clinical 
determinants have been assessed as possible predictors or markers for the presence 
of sleep benefit. An overview of the variables described in different studies is given 
in Table 2. Several studies reported that patients with sleep benefit have an earlier 
age of onset of Parkinson’s disease [10, 11], longer disease duration [9-11] and longer 
medication use [11, 14]. However, others could not confirm this [12, 15], or did not 
include these outcome variables. For none of these determinants opposing outcomes 
were reported in the different studies, pointing to a possible influence of some of these. 
There are very little data on the relationship between objective nighttime sleep quality 
(using polysomnography) in patients with and without sleep benefit. One study performed 
sleep studies, but this yielded no significant group differences for various sleep variables 
[13]. Surprisingly however, there was a trend towards more night awakenings in the 
sleep benefit group. This is in agreement with the findings from another (questionnaire) 
study, that reported more nighttime awakenings in patients with sleep benefit [9]. On the 
other hand, in a study using the Pittsburgh Sleep Quality Index (PSQI), the authors found 
no differences in sleep quality or the number of nighttime awakenings [15].
Medication and sleep benefit
Some studies have assessed the relationship between the use of dopaminergic 
medication and sleep benefit. In one study, patients with sleep benefit used a 
significantly higher daily dose of levodopa (779 mg/day (sd 417) vs. 558 mg/day 
(sd 381)) [11]. However, in other studies these differences in levodopa (equivalent) 
dose were not found [14, 15].
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The hypothesis that patients experiencing sleep benefit may have higher (residual) 
morning levodopa plasma concentrations could not be confirmed, as no differences in 
morning levodopa plasma concentrations were detected [13]. However, a difference in 
response to levodopa was found: following a levodopa-induced “on” period, patients 
with sleep benefit had a more severe inter-dose “off” than those without sleep benefit 
[13]. Merello et al. [9] also reported a significant difference in medication response. 
Forty percent of patients without sleep benefit claimed a significantly greater response 
to the first morning dose of levodopa, whereas the majority (72.5%) of patients with 
sleep benefit described a moderate or minimal response to their first levodopa dose. 
Sleep benefit in genetic and atypical parkinsonism
Sleep benefit has been described in some variants of genetic Parkinson’s disease, and 
variation in the occurrence of sleep benefit between the various genetic mutations 
has been observed. Sleep benefit has been regarded a key clinical feature of PARK2-
linked autosomal recessive juvenile parkinsonism [18-20]. Before the discovery of 
the parkin gene, this familial Parkinsonism was called autosomal recessive juvenile 
parkinsonism with diurnal fluctuations [19]. In these patients, sleep benefit seemed to 
occur at least as much or more often than in idiopathic Parkinson’s disease; a study 
from China reported prevalence numbers of 35.5% and another from Ireland 57% [21, 
22]. In two Japanese studies on the other hand, the prevalence of sleep benefit was 
much higher; 95.3% and 100% [18, 19].
In PARK6-linked autosomal recessive juvenile parkinsonism sleep benefit was 
reported in a few cases as well. However, not all homozygous PARK6/PINK1 mutations 
carry a phenotype with sleep benefit [23-25]. In these genetic variants of Parkinson’s 
disease, sleep benefit was also experienced after both night and daytime sleep 
[18, 24]. The duration of 30-120 min [18] is comparable to the duration in idiopathic 
Parkinson’s disease. The magnitude varied among families and individuals, but the 
phenomenon was especially marked in the earlier stages of the disease [19]. In the 
discussion of other hereditary forms of Parkinson’s disease, sleep benefit was not 
explicitly discussed. Furthermore, we were unable to find reports on sleep benefit 
in atypical parkinsonism’s such as Multiple System Atrophy (MSA) or Progressive 
Supranuclear Palsy (PSP).
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Discussion
It is clear that sleep benefit is an intriguing phenomenon, but many questions remain 
unanswered, which we discuss below. 
Defining sleep benefit
Across studies, we found significant differences in the definition of sleep benefit. It is 
important to consider these differences when interpreting the literature, as they may, 
in part, explain inconsistencies in outcomes. For example, defining sleep benefit as 
either “the best time of the day” or merely as “feeling “on” upon awakening”, is likely 
to make a considerable difference in the results. Therefore, it is of major importance 
that a standardized definition of sleep benefit will be employed in future research. Such 
a definition should incorporate several different aspects of sleep benefit, including 
moment of occurrence, as well as the duration and amount of improvement. We 
propose combining these different aspects into one general definition for sleep benefit:
Sleep benefit is the experience of a temporary decrease in Parkinson’s 
symptoms upon awakening after a period of sleep (night or daytime), before 
drug intake; the patient is feeling as good as “on” (or better).
 
The definition is based on several features. Sleep benefit is not uniquely a morning 
phenomenon, it can occur after daytime sleep as well [9, 15, 17]. There are even 
patients that experience sleep benefit only after a daytime nap and not after nighttime 
sleep [15, 17]. So, in a standardized definition of sleep benefit, we propose that the time 
of occurrence could be generally stated as: “after a period of sleep”. So far, it has not 
been established whether a minimum period of sleep is required for sleep benefit to 
occur. As well, the occurrence or amount of sleep benefit cannot be linked to the time 
spent in a certain sleep stage, so we recommend that the amount of sleep should not 
be part of the definition at this time. In only two previous definitions specific emphasis 
was put on the temporary character of symptom relief caused by sleep benefit [10, 14], 
although this is a key characteristic that is established in all studies. Therefore we 
propose to incorporate this feature in the definition. 
Most importantly, the amount of improvement caused by sleep benefit should 
be addressed. Currently most definitions use “feeling at least as good as in the 
medication induced “on” state” or “best moment of the day” to indicate the amount 
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of improvement. We propose to define sleep benefit as “feeling as good as “on” (or 
better)”, as this forms a clear reference for patients; it points out that sleep benefit 
concerns a specific decrease in Parkinson’s symptoms and avoids confusion with 
e.g. a-specific feeling of being refreshed or an increase in vigilance after sleep. 
Using a relative term for the amount of improvement can also account for individual 
differences.
Subjective versus objective sleep benefit
Note that the proposed definition is stated in subjective terms, because at present, most 
findings have been based on the subjective judgment of patients about the presence 
of sleep benefit. However, there might be a discrepancy between the subjective 
patient experience and their actual motor state. One study reported that several 
patients with sleep benefit described their morning mobility as unrestrained and free 
- comparable to the state experienced after levodopa intake - although their overall 
appearance and objective evaluation using UPDRS were indicative of being in the “off” 
state [13]. No clear cut explanation for this “misperception“ was provided. Studying the 
relationship between the subjective experience and objective motor performance will 
be of major importance in future studies. Until then, it is important to make clear in the 
definition which aspect of sleep benefit is being studied; the subjective experience or 
the objective performance.
In addition to subjective reports, research on sleep benefit is in need of more objective 
measures. Objective measures on sleep benefit are currently scarce. To obtain 
reasonable specificity of a subjective definition, the amount of symptom decrease 
after sleep is defined as “feeling as good as “on” (or better)”. However, this definition 
may have too low sensitivity, as some patients may experience some level of sleep 
benefit, although not as strong as being in the “on” state. In future studies an objective 
quantification of the (minimum) amount of symptom decrease should be determined. 
The same holds for the (minimum) duration of sleep benefit, as currently there are no 
objective studies on the duration of effect.
The choice of whether to use subjective or objective assessment of sleep benefit 
will depend on the situation. For research purposes the definition would preferably 
be stated in objective terms, to guarantee mutual comparability between studies. 
However, in a clinical setting a more pragmatic and subjective approach might be 
more valuable. Possibly, future insights in sleep benefit and the relation between 
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experience and actual motor function, will make it possible to formulate one more 
precise definition of sleep benefit. 
Underlying mechanisms of sleep benefit
There are no formal studies into the underlying mechanisms of sleep benefit. However, 
several hypotheses have been proposed.
Motor fluctuations and sleep benefit
Factor & Weiner [12] suggested that “sleep benefit” actually represents a “morning 
benefit”, probably unrelated to sleep. Specifically, they argued that morning benefit 
is probably related to the time of awakening and pattern of motor fluctuations. These 
motor fluctuations commonly occur in patients who have used levodopa over a longer 
period of time [1]. The findings that patients with sleep benefit often have longer disease 
duration [9-11] and longer medication use [11, 14] would fit with this theory. However, 
other studies showed that patients both with and without fluctuations can experience 
sleep benefit, and that many patients without sleep benefit have motor fluctuations 
[9, 14]. It is not known whether the pattern of motor fluctuations differs between 
patients with and without sleep benefit. The relation between sleep benefit and 
diurnal motor variations has not specifically been studied. Hogl et al. briefly addressed 
the influence of circadian rhythm effects using the Horne-Ostberg morningness-
eveningness questionnaire [13]. They found no difference in self-reported circadian 
type predominance between patients with and without sleep benefit.
The occurrence of sleep benefit after daytime naps, seems to suggest a direct involve-
ment of sleep, regardless of circadian timing. In future research, it would be interesting 
to obtain more data on nap timing, duration and frequency; to see whether the oc-
currence of sleep benefit after daytime naps can be explained by a (circadian) pattern 
of motor fluctuations. Longitudinal assessment of Parkinson’s symptoms, using ac-
tigraphy, sleep diaries or pre and post-sleep measures over several days might also 
provide more insights on this.
Direct effects of sleep
In the alternative major hypothesis, sleep benefit has been attributed to improved 
dopaminergic function as a result of increased dopamine storage in nigral neuronal 
terminals during sleep [9, 10, 14]. 
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Sleep benefit generally occurs upon awakening in the morning, therefore, this 
phenomenon is often intuitively linked to sleep. This hypothesis is supported by the 
observation that sleep benefit also occurs after daytime periods of sleep. However, not 
all patients that experience sleep benefit after nighttime sleep do so after a daytime 
nap. And conversely, some patients do experience sleep benefit after a nap, but not 
after nighttime sleep [9, 15, 17]. Daytime naps are generally shorter than nighttime 
sleep, which could explain why not all patients that experience sleep benefit in the 
morning also experience this after a daytime nap. Patients that only experience sleep 
benefit after a daytime nap may provide additional insights, but this particular group 
has never been studied explicitly. The only reported finding is that PSQI scores of 
these patients did not differ from those patients who regularly took a nap [15]. This 
suggests that the absence of sleep benefit in the morning cannot be explained by 
severely disrupted nighttime sleep.
The only polysomnographic study was unable to link sleep benefit to a specific sleep 
measure, for example total sleep time, amount of slow wave sleep or amount and 
latency of REM sleep [13]. However, these data are from only one study, including 10 
patients with sleep benefit. To establish whether there is a link between sleep benefit 
and sleep, much more attention should be devoted to the period of sleep preceeding 
the period of sleep benefit.
Further research on daytime naps might be a useful starting point in unraveling 
whether sleep benefit is related to sleep per se. A nap paradigm is regularly used in 
studies on the influence of sleep [26-29]. Shorter periods of sleep can be as informative 
(and effective) as a whole night [26] and are much more convenient in an experimental 
setting. Naps are less sensitive to the effects of circadian rhythm and distorted results 
due to extreme sleepiness in controls who underwent a night of (partial) sleep 
deprivation can be avoided. 
Furthermore, the use of (functional) imaging techniques, which have developed spec-
tacularly in recent years, may contribute to a better understanding of sleep benefit. 
Studying the possible presence of sleep benefit in other (neurodegenerative) disorders, 
for example episodic ataxia [30], hereditary progressive dystonia [31, 32] or Lewy body 
dementia could also lead to new insights in the mechanisms underlying sleep benefit. 
Finally, the variation in the presence of sleep benefit between various genetic forms of 
parkinsonism is interesting and may yield further pathophysiological clues.
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Sleep deprivation benefits
As some studies showed (a trend to) more sleep disruption including a higher number 
of nighttime awakenings in patients with sleep benefit [9, 13], another hypothesis was 
raised. Sleep benefit could be independent from sleep quality, or sleep deprivation 
could even facilitate sleep benefit. The beneficial clinical effects of sleep deprivation are 
also known in for example depression [33].
This hypothesis initially seemed to be supported by a PET study, that found higher 
levels of dopamine after sleep deprivation in healthy controls [34]. However, a recent 
experiment showed that these results were caused by a down regulation of dopamine 
receptors instead of an increase in dopamine levels [35]. Together with the varying 
results for the amount of nighttime awakenings in sleep benefit this ‘sleep deprivation 
hypothesis’ does not seem likely.
Clinical implications 
Not all healthcare professionals are familiar with sleep benefit and its potential 
favourable influence on Parkinson’s symptoms. An interesting question is whether a 
clinical application of sleep benefit can be found. With the current difficulties of (long 
term) medication therapy in mind, the clinical implications of sleep benefit could be 
promising. With a clinical improvement that lasts for an average duration of about 80 
minutes, sleep benefit may indeed have relevant therapeutic application. First, during 
the period of sleep benefit after nighttime sleep, patients might be able to get out 
of bed, get dressed and have breakfast even before they take their first medication. 
Merello et al. [9] reported that 21% of their patients were able to skip or delay their 
morning medication because of sleep benefit. Such an adjustment in the medication 
schedule could allow patients to extend the proportion of the day spent in a good 
“on” phase, although this assumption remains untested. Second, some patients also 
experience sleep benefit after daytime sleep. In such patients, scheduled power 
naps could be prescribed therapeutically to buttress levodopa therapy in the early 
afternoon, at a time when medication doses tend to become less effective for most 
patients, presumably due to receptor adjustments [36]. It remains to be seen whether 
interventions to increase nighttime sleep duration and/or quality may have subsequent 
effects on sleep benefit. Furthermore, future studies may focus on the possible 
extension of sleep benefit to the non-motor symptoms of Parkinson’s disease. Finally, 
a better understanding of sleep benefit and its underlying mechanisms could lead to a 
better understanding of Parkinson’s disease and the function of human sleep.
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Abstract
Introduction: Parkinson’s disease patients may experience ‘sleep benefit’: a 
temporarily improved mobility upon awakening. Sleep benefit has mainly been studied 
retrospectively using questionnaires, but it remains unclear whether it is associated 
with actual changes in motor functioning.
Methods: We performed a prospective study on sleep-related changes in motor 
functioning, using a Parkinson’s symptom diary during 7 days in 240 randomly 
selected Parkinson’s patients (140 men; 66.8±9.6 years; disease duration 9.3±6.2 
years). Afterwards, patients received a questionnaire on the possible subjective 
experience of sleep benefit. 
Results: Using the Parkinson’s symptom diary, a positive change in motor function was 
observed after 267 nights (17.8%) and after 138 daytime naps (23.4%). Based on these 
results, 75 patients (32%) were classified as having sleep benefit. In response to the 
subsequent questionnaire, 73 patients (31%) reported sleep benefit. Interestingly, the 
groups with sleep benefit according to either the diary or the questionnaire overlapped 
only partially: outcomes were congruent in 63% of subjects (both negative 49%, both 
positive 14%). In both the diary and questionnaire, patients with sleep benefit showed 
a longer disease duration and longer medication use. According to the questionnaire, 
there was a trend towards a shorter sleep duration and lower sleep efficiency in the 
sleep benefit group. The mean change in motor function after sleep as assessed using 
the diary was higher in patients reporting subjective sleep benefit.
Conclusion: We show that the subjective experience of sleep benefit in Parkinson’s 
disease is not always related to an actual increase in reported motor function after sleep. 
Defining sleep benefit using either a symptom diary or a questionnaire on subjective 
experience, results in only partly overlapping groups. These data suggest that sleep 
benefit may be a more heterogeneous phenomenon than previously thought and that 
subjective experience of symptom severity is not necessarily related to actual motor 
function. 
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Introduction
Sleep in Parkinson’s disease is generally associated with sleep disorders, which affect 
60-98% of Parkinson’s patients [1-3]. However, clinicians have repeatedly noted reports 
of patients experiencing a Parkinson-specific beneficial effect of sleep. Contrary to 
what would be expected after a night without medication, some patients describe a 
temporarily improved mobility upon awakening. In the early eighties, Marsden was the 
first to describe this phenomenon, coining the term “sleep benefit” [4]. Subjective patient 
reports suggest that the effect of sleep benefit may be rather pronounced, with patients 
sometimes comparing sleep benefit to the “on” state as induced by dopaminergic 
medication. Some Parkinson’s patients can even delay or skip their morning dose of 
medication because of sleep benefit [5]. Although typically described after nocturnal 
sleep, sleep benefit may also occur after daytime naps [5-8]. In this study, we assess sleep 
benefit using a recently suggested, explicit definition: Sleep benefit is the experience of 
a temporary decrease in Parkinson’s symptoms upon awakening after a period of sleep 
(night or daytime), before drug intake; the patient is feeling as good as “on” (or better) [9].
In most studies, questionnaires have been used to evaluate the prevalence and 
characteristics of sleep benefit. Results showed a rather consistent prevalence 
estimate, ranging from 33 to 55% of Parkinson’s patients who recognized the 
phenomenon [9]. However, it remains unknown why some patients experience sleep 
benefit while others do not. Possible determinants of sleep benefit were assessed by 
several research groups, including age, age at onset, disease duration and presence 
of motor fluctuations [5, 6, 8, 10-12]. Results varied widely and no consistent sleep 
benefit-associated variables have been found to date. One explanation for this may 
be the prominent differences in the definition of sleep benefit that were applied in 
the various studies [9]. Furthermore, patients often have difficulties giving an accurate 
account of their general motor functioning after sleep [13].
Here we performed a prospective study in a large group of Parkinso’s patients using 
tailored symptom diaries. In the diary, patients provided an indication of specific 
motor functioning before and directly after every period of sleep. Using this approach, 
we obtained sleep-related changes in subjective motor functioning over multiple 
days, without explicitly asking patients about the phenomenon of sleep benefit. The 
objective of this study was to gain more insight into the nature of sleep benefit and the 
magnitude of its effect.
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Methods
Subjects
Information letters about the study were sent to 475 Parkinson’s patients under 
treatment at the Parkinson Centre Nijmegen and the associated national ParkinsonNet. 
Subsequently, these patients were contacted by telephone to provide general study 
information and - when interested - to book an appointment for completing the sleep 
benefit-diary. After telephone consultation, 292 patients agreed to participate, of which 
240 patients completed both the diary and questionnaire. The study was approved by 
the Medical Ethical Committee of the Radboud university medical centre. All patients 
provided written informed consent to participate.
Diary
The symptom diary was based on the SCOPA Diary Card (SCOPA DC) [14], a validated 
instrument to assess changes in motor functioning during the day. Before and directly 
after every night of sleep and every daytime nap, patients answered four questions with 
respect to Parkinson-related motor functioning. The diary was completed at bedtime 
and directly at awakening, before medication intake. Patients indicated on a four-point 
scale how well they could perform three activities, i.e. walking, changing position and 
using their hands. These activities have proven to give a reliable indication of general 
motor functioning [14]. In addition, the question on sleep quality from the SCOPA DC 
was used and we added an extra question on feeling rested upon awakening, all 
recorded using four-point Likert scales.
Medication taken within 2 hours before a period of sleep or during the night-time was 
recorded in the diary. All dopaminergic medication was converted into the L-dopa 
equivalent dose (LED), using the formula described by Tomlinson et al. [15]. 
Patients completed the symptom diary during one week, before and directly after every 
period of sleep (both night sleep and daytime naps). Importantly, in this phase of the 
study, patients were not explicitly informed about the phenomenon of sleep benefit.
Questionnaire
After completing the diary week, patients received an extensive questionnaire, in which 
demographic characteristics and clinical information were obtained. The Pittsburgh 
Sleep Quality Index (PSQI) provided a validated measure of nocturnal sleep quality 
during the past month [16], therefore the questionnaire had to be completed within a 
month after the symptom diary.
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Subsequently, a brief explanation of sleep benefit was given in the questionnaire. 
This explanation of sleep benefit was based on the revised definition of sleep benefit 
recently presented by our group [9]. Afterwards, patients were asked whether they 
were familiar with sleep benefit, and if yes, how often they experienced it. Finally, 
information was obtained on the duration, degree of improvement and variability of 
the sleep benefit experience. 
Analyses
For all analyses, night sleep and daytime naps were regarded separately. Motor 
functioning was defined as the sum of the three functioning questions in the diary 
(i.e. walking, changing position, using hands). Changes in motor function in relation to 
sleep were calculated by subtracting post-sleep motor scores from pre-sleep motor 
functioning. This was done for every period of sleep separately. 
A night with a positive change (better functioning in the morning than in the evening) 
was regarded as a “sleep benefit-night”. The same approach was used for daytime 
naps. Patients were classified as having sleep benefit, when sleep benefit was present 
after at least 2 nights or 2 naps during the 7 day period. 
All analyses were performed in SPSS for Windows version 20. Groups with and without 
sleep benefit were compared using t-tests or chi2-tests. Correlations were analyzed 
using Spearman’s correlations. Alpha was set to 0.01 to correct for multiple comparisons. 
Results
Of the 292 participating patients, a total of 240 completed the 7-day motor diary and 
the subsequent sleep benefit questionnaire. Mean age was 66.8 ± 9.6 years (range 
33-94 years) and the number of men was 140 (58.3%). Mean disease duration was 9.3 
± 6.2 years (range 1-35 years), with a mean age of Parkinson’s disease onset of 57.4 
± 12.2 years (range 22-87 years). The most important reasons for dropout were: illness 
(25), patients considering the symptom diary too confronting and/or demanding 
(16) and being lost to follow up (9). Patients dropping out were older than those who 
finished the diary (72.3 ± 10.6 vs. 66.8 ± 9.6 years, p<0.001) but there were no gender 
differences between the groups.
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Sleep benefit diary
In 5 diaries more than 50% of the questions were missing; these diaries were excluded 
from the analyses. Valid information was obtained from a total of 1496 nights (91%) and 
591 (90%) naps (mean duration 21.7 ± 45.9 min). A positive change in motor function 
was observed after 267 nights (17.8%), and after 138 naps (23.4%). Based on these 
results, 76 patients (32%) were classified as having sleep benefit, 44 (58%) patients 
only showed sleep benefit after night sleep, 11 (14%) only after an afternoon nap and 
21 (28%) patients after both. None of the patients had sleep benefit after every night 
of the week. In table 1, the number of patients are listed with the number of nights 
associated with a positive change in motor function, over the measurement week. 
When comparing patients with and without sleep benefit based on the symptom 
diary, we found that patients with sleep benefit had used Parkinson’s medication over 
a longer period of time and showed a trend towards longer disease duration (table 2).
There were no differences in gender distribution, age, or sleep quality between 
patients with and without sleep benefit. 
Table 1  | Patient report of total number of nights per week with sleep benefit
        according to the Parkinson’s symptom diary
Number of sleep benefit nights per week Patients n(%)
0 111 (47.2%)
1 59 (25.1%)
2 25 (10.6%)
3 19 (8.1%)
4 8 (3.4%)
5 9 (3.8%)
6 4 (1.7%)
7 0 (0%)
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Table 2  |  Characteristics of patients with and without sleep benefit 
SB based on diary SB based on questionnaire
SB no-SB p SB no-SB p
SB 76 (32%) 159 (68%) 74 (31%) 163 (69%)
Men 43 (57%) 94 (59%) 0.741 37 (50%) 102 (63%) 0.068 
Age (yrs) 67.3 ± 9.7 66.3 ± 9.6 0.454 63.6 ± 8.2 68.5 ± 9.7 0.000*
Age PD onset (yrs) 56.6 ± 13.6 57.5 ± 11.5 0.587 51.9 ± 11.1 60.0 ± 11.9 0.000*
Duration of PD 
symptoms (yrs)
10.8 ± 7.0 8.7 ± 5.8 0.019 11.7 ± 6.7 8.2 ± 5.7 0.000*
Duration
medication use (yrs)
9.0 ± 6.0 6.8 ± 5.5 0.009* 9.4 ± 6.3 6.5 ± 5.3 0.001*
Daily LED (mg) 752 ± 608 624 ± 409 0.080 804 ± 614 584 ± 382 0.002*
PSQI 7.5 ± 3.9 7.2 ± 3.9 0.680 7.8 ± 4.1 7.0 ± 3.8 0.178
Sleep duration
(hrs - PSQI)
6.7 ± 1.3 6.7 ± 1.6 0.960 6.4 ± 1.3 6.8 ± 1.5 0.039
Sleep efficiency  
(% - PSQI)
78.7 ± 16.1 78.2 ± 17.7 0.840 74.9 ± 14.7 80.3 ± 17.9 0.027
Diary – 5 missing, Questionnaire – 3 missing, PD | Parkinson’s disease, SB | Sleep benefit  
* significant difference at α = 0.01
In the sleep benefit group, 22 patients (28.9%) used long-acting L-dopa and 5 patients 
(6.6%) used dopamine agonists in the 2 hours before bedtime. In the no-sleep benefit 
group, 30 patients (19.1%) used long-acting L-dopa and 13 patients (8.3%) used 
dopamine agonists in the 2 hours before bedtime. Benzodiazepines were sometimes 
used by 9 sleep benefit patients (12%) and 18 no-sleep benefit patients (11.5%) and 
other sleep modulating drugs were used by 11 patients with sleep benefit (14.7%) and 
18 patient without sleep benefit (11.5%). For none of these drugs there was a significant 
between-group difference.
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When looking at individual nights, we found no significant correlations between the 
amount of overnight change in motor functioning and self-rated sleep time, sleep 
quality or the feeling of being rested upon awakening. In addition, we found no influence 
of the amount of dopaminergic medication taken before and/or during the night on the 
occurrence of sleep benefit. For the daytime naps, no association was found between 
the amount of functioning change after sleep and sleep time, sleep quality, restorative 
feeling or dopaminergic medication taken within 2 hours before the nap either. 
Sleep benefit questionnaire
In the questionnaire, 74 patients (31%) indicated to experience sleep benefit. When 
patients were categorized based on their own subjective judgment on the presence 
of sleep benefit in the questionnaire, we found that the sleep benefit group not only 
had a longer disease duration and a longer history of medication use, but also a higher 
daily L-dopa equivalent dose (table 2). In addition, patients reporting sleep benefit 
were younger, and had an earlier age of onset of Parkinson’s disease. There were no 
differences in overall subjective sleep quality as assessed by the PSQI between the sleep 
benefit and no-sleep benefit group, although there was a trend towards a shorter sleep 
duration as well as a lower sleep efficiency in patients reporting sleep benefit (table 2). 
Additional information on the characteristics of subjective sleep benefit were obtained 
in the questionnaire as well. Of the patients recognizing sleep benefit, the majority 
reported to  experience sleep benefit on a regular basis. Strikingly, 28% of patients even 
reported that they always experienced sleep benefit. The mean estimated duration of 
sleep benefit was 1:03 ± 0:53 hours. At awakening, 47.1% reported to feel “as good as 
on medication” and 22.9% reported to feel even better. The remaining 30% of patients 
experienced an improvement in functioning, but perceived it not as good as when on 
medication. About a third of the subjects (31.5%) indicated to experience sleep benefit 
during the night, for example when going to the toilet. Many patients had the feeling 
that sleeping longer (47.3%) or shorter (58.1%) had an influence on the occurrence of 
sleep benefit. 
Comparing sleep benefit diary and questionnaire outcomes
Interestingly, the group of patients classified as having sleep benefit based on the 
symptom diary, overlapped only partially with the group of patients self-reporting 
to have sleep benefit in the questionnaire (table 4). Outcomes of the diary and the 
questionnaire were congruent in only 63% of the subjects (both negative 49%, both 
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Table 3  |  Patients description of sleep benefit 
Descriptions characteristic for sleep benefit
• “At awakening I feel less rigid, I feel I could skip my medication  if I want to”
• “After a nap I move faster, more flexible and more natural”
• “After sleeping I feel like I don’t have Parkinson’s disease, even my handwriting is as 
good as it used to be”
• “Sometimes I forget to take my morning medication, because I feel so good”
• “For me sleep is the best drug against Parkinson’s disease”
• “After a nap it feels like my body is reset” 
• “At awakening in the morning I can go to the toilet by myself, whereas during the rest of 
the day I need help with everything”
Descriptions non-characteristic for sleep benefit 
(i.e. general a-specific sleep effects)
• “I feel very rested, however, I’m still very rigid”
• “I feel less tired after an afternoon nap”
• “In the morning I have more energy than in the afternoon”
• “After sleeping I feel more relaxed”
positive 14%). A relevant portion of patients (18%) reported to have sleep benefit, but 
did not show improvement on the diary. A comparable 19% of subjects did show 
motor improvement after sleep in the diary, but did not perceive themselves as having 
sleep benefit. 
We also asked patients experiencing sleep benefit to give their own written description 
of how they feel at waking up. Some patients gave very characteristic and specific 
descriptions fitting with sleep benefit (table 3). However, there were also patients 
who rated themselves as having sleep benefit, who provided a much more general 
description of feeling improved at awakening, which would fit more with a-specific 
refreshing effects of sleep (table 3).
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As the groups with sleep benefit according to either the diary or the questionnaire were 
not fully overlapping, we combined the outcomes of both instruments in an additional 
analysis, which indicated that both instruments may probe different aspects of sleep 
benefit. Patients with and without diary-determined sleep benefit, did not report 
differences in the characteristics and experience of their perceived sleep benefit in 
the questionnaire. Moreover, unusual, ‘non-characteristic’ sleep benefit descriptions 
(e.g. “I feel less tired” or “I have more energy”) could be provided by patients both with 
and without sleep benefit according to the diary. Conversely, some patients with very 
clear, characteristic and convincing descriptions of sleep benefit in the questionnaire, 
did not show any improvement in subjective motor function related to sleep in the 
prospective diary.
Table 4  |  Number of patients with sleep benefit based on diary or questionnaire
SB based on diary Total
no-SB SB
SB based on 
questionnaire
no-SB 115 (72.3%) 44 (27.7%) 159
SB 41 (56.2%) 32 (43.8%) 73
Total 156 76 232
SB | sleep benefit
Percentage shown: within sleep benefit based on questionnaire.
Motor function changes after a daytime nap were larger in patients subjectively 
reporting sleep benefit in the questionnaire, compared to those not reporting sleep 
benefit (mean improvement 0.53 ± 1.54 vs. 0.06 ± 0.78 respectively, p < 0.001). A trend 
was found in the similar direction when looking at overnight changes in motor function 
(mean improvement in patients with subjective sleep benefit 0.01 ± 1.53 vs. -0.12 ± 
1.06 in patients without, p = 0.052).
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Discussion
The existence of sleep benefit in Parkinson’s disease has been reported repeated-
ly in the literature [1, 4-6, 8, 10-13]. Here, we examined subjective sleep benefit in 
a structured, prospective design using a 7-day diary. Additionally, we compared the 
diary responses to a more traditional way of assessing sleep benefit using a question-
naire. As such, the present study represents the first prospective assessment of sleep 
benefit over a longer period of time. Using either instrument, we found a prevalence 
of subjective sleep benefit of just over 30% and the sleep benefit group had longer 
medication use and a tendency towards shorter night sleep. Remarkably, the groups 
with sleep benefit according to the diary and according to the self-report question-
naire were overlapping only partially. Many patients showed incongruent results on 
the diary and the questionnaire; they either showed improvement in the diary, but did 
not report to experience this improvement in the questionnaire, or they reported to 
experience an improvement after sleeping in the questionnaire that was not present 
in the diary. Nevertheless, the mean change in motor function after sleep tended to be 
higher in patients reporting subjective sleep benefit. 
We applied a new approach in studying sleep benefit, using a diary in which structured 
questions about motor functioning reflected the subjective motor symptom severity at 
that moment. The diary enabled us to prospectively study patients for more than one 
night. Furthermore, patients did not have to indicate their general morning function, 
but assessed their functioning at a specific moment on specific motor domains. This 
was the first study that addressed over-night functioning change over a longer period 
of time. We chose to do this, to see whether there was any day-to-day variation in 
sleep-related symptom severity changes in Parkinson’s disease. In previous research, 
sleep benefit has been treated as an “all or nothing” phenomenon, classifying patients 
as having either sleep benefit or not at all. Here we show that this is not necessarily the 
case. From both the diary and the questionnaire it became clear that in the majority 
of patients, sleep benefit was not experienced after every period of sleep. Although 
29% of sleep benefit patients (according to the questionnaire) claimed that their sleep 
benefit was ‘always’ present, none of the patients had a positive change in functioning 
in all of the diary nights. 
Our questionnaire provided a carefully formulated definition of sleep benefit to 
make it as clear as possible for the patients what we were looking for. However, the 
Sleep benefit in Parkinson’s disease
64
written description of their experiences indicated that some patients may still have 
misinterpreted the given definition. Although it was stated that sleep benefit is a specific 
reduction in Parkinson’s symptoms, some patients confused it with more general and 
a-specific refreshing effects of sleep, which are not necessarily related to Parkinson’s 
disease. We previously established this problem and attributed this to the ill-defined 
description of sleep benefit in earlier studies [9]. We feel that our strict definition 
increased the specificity to detect sleep benefit, which also fits with the prevalence of 
31% in our cohort, which is slightly lower than in previous reports.
In our explanation of sleep benefit in the questionnaire, it was stated that the decrease 
in Parkinson’s symptoms should be as good as feeling “on” (or better). However, 30% 
of the patients who reported sleep benefit in the questionnaire, subsequently stated 
that a symptom decrease was present after sleep, but not as large as when under the 
effect of medication. This may have caused an overestimation of the prevalence of 
sleep benefit. On the other hand, among the patients that answered negatively to the 
sleep benefit question, there were probably also patients who do experience some 
improvement after sleep, although not as large as on medication. Our data certainly 
indicate that there is large variation in the degree of symptom change by sleep 
benefit. Here -as well as in previous studies- some of the patients may have (partly) 
misinterpreted the sleep benefit definition, incorrectly stating to experience sleep 
benefit. Nevertheless, the characteristic written descriptions given by some patients, 
indicate that there may indeed be a group of Parkinson’s patients that genuinely 
benefits from sleep. 
Even patients with a highly characteristic and convincing description of perceived 
sleep benefit, did not always show sleep related symptoms changes in the diary. 
Therefore, the incongruence between the results from the diary and the questionnaire 
may further imply that these instruments assess different aspects of sleep benefit. 
When discussing sleep benefit, it seems necessary to make a distinction between 1 |  a 
subjective general feeling of improvement after sleep and 2 |  a specific improvement 
in actual motor functioning. Both aspects may contribute to the experiences which 
patients perceive as sleep benefit. The latter aspect was mostly assessed by the 
symptom diary, as we specifically targeted this instrument towards changes in motor 
function. The definition of sleep benefit in the questionnaire could be interpreted in 
a more general way, including non-motor symptoms of Parkinson’s disease and/or 
a-specific refreshing effects of sleep. Both aspects could for sure be clinically relevant, 
65
4 |  Prospective assessment of sleep benefit
4
but the underlying mechanisms are possibly different. Therefore, this distinction 
should be an important point of focus in future research. 
We have assessed possible determinants of sleep benefit in our cohort. In both 
the diary- and questionnaire-determined sleep benefit we found that patients with 
sleep benefit had longer disease duration and longer medication use. Using the 
questionnaire we also found that patients with sleep benefit were younger, had a lower 
age of onset and used higher doses of dopaminergics. Similar results have previously 
been found for disease duration [5, 10, 11], medication use [6, 11], age of onset [10, 11] 
and LED [10, 11]. Only one other study has reported a difference in age between sleep 
benefit and no-sleep benefit patients, but found sleep benefit patients to be older [5]. 
In the diary data we found a negative correlation with the magnitude of sleep benefit 
and self-reported sleep duration and quality. In addition, in the questionnaire a trend 
towards shorter sleep duration and lower sleep efficiency was present in the sleep 
benefit group. This possible association with shorter and/or worse nighttime sleep with 
the presence of sleep benefit is in line with a recent polysomnography study in which a 
shorter total sleep time and a longer sleep latency were found in patients experiencing 
sleep benefit [17]. Together, these data may suggest that sleep benefit is in fact not 
related to sleep, or even that sleep deprivation facilitates sleep benefit. This hypothesis 
has been put forward in the literature before [5, 13]. When a causal relation between 
(good) sleep and improved motor function is abandoned, the thinking about the 
putative mechanism underlying sleep benefit may also have to change. The currently 
most common hypothesis states that dopamine storage in nigral neuronal terminals 
are replenished during sleep as the mediator of sleep benefit [9]. However, this would 
not fit with the association between poorer sleep quality and sleep benefit, although it 
should be noted that these results are all based on the evaluation of nocturnal sleep. 
Sleep benefit is also reported after daytime naps [5-8]; and assessing nap related 
sleep benefit may shed further light on possible underlying mechanisms. Our study 
however, is unsuitable for making strong inferences on these mechanistic aspects.
This study had some limitations. In the diary we could only record planned naps, as it 
was essential that the patient completed the diary both before and after a sleep episode. 
We probably missed some unplanned and unnoticed sleep episodes [18]. However, 
as our classification of patients having sleep benefit relied on an minimum number 
of naps with a positive change, this could at worst have led to an underestimation 
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of patients with sleep benefit based on daytime naps. Furthermore, self-reports of 
sleep quality are not always reliable and subjective to various factors including affective 
disorders [19]. However, previous studies on sleep benefit that included assessment 
of depressive symptoms did not find differences between patients with and without 
sleep benefit [8, 17]. 
As patients dropping out of the study were older and may have been different with 
respect to disease duration or severity, one should be careful to generalize our findings 
to the whole Parkinson’s population.
We used a minimum of 2 nights or naps with any symptom improvement as a cut-off 
for sleep benefit. Because this was the first time that sleep benefit was studied using a 
symptom diary, we had to choose cut-off values. For this particular study, we chose to 
be relatively sensitive and to classify any amount of ‘over-sleep improvement’ that oc-
curred for more than one day as indicative of sleep benefit. Although arbitrary, this is at 
least a very clear way of defining sleep benefit, allowing comparisons between studies. 
Conclusions
We showed that the subjective experience of sleep benefit in Parkinson’s is not always 
related to an actual increase in reported motor function after sleep. Defining sleep 
benefit using either a symptom diary or a questionnaire on subjective experience, 
probed different aspects of the phenomenon, resulting in only partly overlapping 
groups. These data suggest that sleep benefit may be a more heterogeneous 
phenomenon than previously thought and that subjective experiences of symptom 
severity is not necessarily related to actual motor function. 
Given its potential clinical relevance as therapeutic intervention, there is now a crucial 
need for detailed prospective studies using quantitative objective measures of motor 
performance, in relation to objective assessment of sleep quality. Such studies should 
also monitor the effects of sleep benefit on non-motor symptoms of Parkinson’s 
disease, including cognitive deficits and fatigue, as these may potentially improve in 
relation to sleep as well. 
67
4 |  References
References 
1 | Comella CL: Sleep disorders in Parkinson’s disease: an overview. Movement disorders : 
official journal of the Movement Disorder Society 2007, 22 Suppl 17:S367-373.
2 | Askenasy JJ: Sleep disturbances in Parkinsonism. Journal of neural transmission 2003, 
110:125-150.
3 | Louter M, Aarden WC, Lion J, Bloem BR, Overeem S: Recognition and diagnosis of sleep 
disorders in Parkinson’s disease. J Neurol 2012, 259:2031-2040.
4 | Marsden CD: “On-off” phenomena in Parkinson’s disease. In Parkinson’s disease: current 
progress, problems and management. Edited by Rinne U, Klinger M, Stamm G. Amsterdam: 
Elsevier; 1980: 241-254
5 | Merello M, Hughes A, Colosimo C, Hoffman M, Starkstein S, Leiguarda R: Sleep benefit in 
Parkinson’s disease. Movement disorders : official journal of the Movement Disorder Society 
1997, 12:506-508.
6 | Tandberg E, Larsen JP, Karlsen K: Excessive daytime sleepiness and sleep benefit in 
Parkinson’s disease: a community-based study. Movement disorders : official journal of the 
Movement Disorder Society 1999, 14:922-927.
7 | Pal PK, Thennarasu K, Fleming J, Schulzer M, Brown T, Calne SM: Nocturnal sleep 
disturbances and daytime dysfunction in patients with Parkinson’s disease and in their 
caregivers. Parkinsonism & related disorders 2004, 10:157-168.
8 | van Gilst MM, Louter M, Baumann CR, Bloem BR, Overeem S: Sleep benefit in Parkinson’s 
disease: Time to revive an enigma? Journal of Parkinson’s disease 2012, 2:167-170.
9 | van Gilst MM, Bloem BR, Overeem S: “Sleep benefit” in Parkinson’s disease: A systematic 
review. Parkinsonism & related disorders 2013, 19:654-659.
10 | Bateman DE, Levett K, Marsden CD: Sleep benefit in Parkinson’s disease. Journal of 
neurology, neurosurgery, and psychiatry 1999, 67:384-385.
11 | Currie LJ, Bennett JP, Jr., Harrison MB, Trugman JM, Wooten GF: Clinical correlates of 
sleep benefit in Parkinson’s disease. Neurology 1997, 48:1115-1117.
12 | Factor SA, Weiner WJ: ‘Sleep benefit’ in Parkinson’s disease. Neurology 1998, 50:1514-1515.
13 | Hogl BE, Gomez-Arevalo G, Garcia S, Scipioni O, Rubio M, Blanco M, Gershanik OS: A 
clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson’s 
disease. Neurology 1998, 50:1332-1339.
14 | Marinus J, Visser M, Stiggelbout AM, Rabey JM, Bonuccelli U, Kraus PH, van Hilten JB: 
Activity-based diary for Parkinson’s disease. Clin Neuropharmacol 2002, 25:43-50.
15 | Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE: Systematic review of levodopa 
dose equivalency reporting in Parkinson’s disease. Movement disorders : official journal of 
the Movement Disorder Society 2010, 25:2649-2653.
16 | Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep 
Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 
28:193-213.
17 | Sherif E, Valko PO, Overeem S, Baumann CR: Sleep benefit in Parkinson’s disease is 
associated with short sleep times. Parkinsonism & related disorders 2014, 20:116-118.
4
Sleep benefit in Parkinson’s disease
68
18 | Bolitho SJ, Naismith SL, Salahuddin P, Terpening Z, Grunstein RR, Lewis SJ: Objective 
measurement of daytime napping, cognitive dysfunction and subjective sleepiness in 
Parkinson’s disease. PLoS One 2013, 8:e81233.
19 | Aitken D, Naismith SL, Terpening Z, Lewis SJ: Dysfunctional sleep beliefs in Parkinson’s 
disease: relationships with subjective and objective sleep. J Clin Neurosci 2014, 21:1359-
1363.
69
4
4 |  References
five
571
five
Published as:
van Gilst, M.M., van Mierlo, P., Bloem, B. R., Overeem, S. 
Quantitative Motor Performance and Sleep Benefit in Parkinson Disease. 
Sleep, 2015 Mar 26. pii: sp-00507-14
Quantitative motor 
performance and 
sleep benefit
Sleep benefit in Parkinson’s disease
72
Abstract
Introduction: Many people with Parkinson disease experience “sleep benefit”: 
temporarily improved mobility upon awakening. Here we used quantitative motor 
tasks to assess the influence of sleep on motor functioning in Parkinson disease. 
Methods: Eighteen Parkinson patients with and 20 without subjective sleep benefit 
and 20 healthy controls participated. Before and directly after a regular night sleep 
and an afternoon nap, subjects performed the timed pegboard dexterity task and 
quantified finger tapping task. Subjective ratings of motor functioning and mood/
vigilange were included. Sleep was monitored using polysomnography. 
Results: On both tasks, patients were overall slower than healthy controls (night: 
F2,55 = 16.938, p < 0.001; nap: F2,55 = 15.331, p < 0.001). On the pegboard task, there was 
a small main effect of night sleep (F1,55 = 9.695, p = 0.003); both patients and controls 
were on average slightly slower in the morning. However, in both tasks there was no 
sleep*group interaction for nighttime sleep nor for afternoon nap. There was a modest 
correlation between the score on the pegboard task and self-rated motor symptoms 
among patients (rho = 0.233, p = 0.004). No correlations in task performance and 
mood/vigilance or sleep time/efficiency were found. 
Conclusions: A positive effect of sleep on motor function is commonly reported by 
Parkinson patients. Here we show that the subjective experience of sleep benefit is 
not paralleled by an actual improvement in motor functioning. Sleep benefit therefore 
appears to be a subjective phenomenon and not a Parkinson-specific reduction in 
symptoms. 
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Introduction
Sleep disorders are highly prevalent among patients with Parkinson disease. However, 
there are also reports of Parkinson patients experiencing a beneficial effect of sleep. 
Upon awaking in the morning, many patients experience an improved mobility as if 
they are in a medication-induced “on” state, contrary to what would be expected after 
a night without medication. This intriguing phenomenon is known as “sleep benefit” [1]. 
Some Parkinson patients are even able to delay or skip their morning dose of 
medication because of this sleep benefit [2]. According to questionnaire studies, the 
prevalence of sleep benefit is consistently reported to be quite high, with 33% to 55% of 
Parkinson patients reporting to experience sleep benefit [2, 3].
Studies using objective measures of sleep benefit are limited in number so far. A few 
studies assessed motor performance using the Unified Parkinson’s Disease Rating 
Scale (UPDRS) motor scale [4, 5]. In the Högl study, there was no difference in morning 
function between patients with and without subjective sleep benefit. However, 
comparisons between evening and morning status showed an improvement in motor 
function in those patients reporting sleep benefit, and a deterioration in patients 
without [5]. 
Although widely used, the UPDRS strongly depends on the observer and is time-
consuming. Attractive alternative measures for motor fuction are available, such as the 
pegboard dexterity test, which is a fast and sensitive instrument to objectively and 
quantitatively evaluate motor dysfunction in Parkinson disease [6-8]. Additionally, 
bradykinesia can be quantified using an alternating finger tapping task (digitography) 
[9]. Both tests correlate well with the UPDRS III [7, 10]. Therefore, the pegboard 
dexterity test and finger tapping task appear to be excellent tools to assess the motor 
correlates of sleep benefit. In this study, we used these quantitative motor tasks to 
assess possible changes in motor function after a period of sleep in Parkinson patients. 
We compare and describe sleep-related changes in motor function in patients that 
report to experience sleep benefit, those who do not and in healthy elderly controls. 
We focus not only on nighttime sleep but also on daytime naps, and assess the quality 
and characteristics of the preceding period of sleep (using polysomnography) and 
subjective ratings of motor function and mood/vigilance to examine whether these are 
related to changes in motor functioning.
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Methods
Patients
Patients were recruited from a cohort of 240 Parkinson patients who completed both 
a questionnaire and a diary on sleep benefit. Patients filled out a daily symptom diary 
before and directly after sleep for 7 consecutive days, in which they subjectively rated 
different aspects of their motor functioning (see measures section for more details). 
A night with a positive change of at least one point (better functioning in the morning 
than in the evening) was regarded as a “sleep benefit-night.” The same approach was 
used for daytime naps. Patients were classified as having sleep benefit, when sleep 
benefit was present after ≥2 nights or 2 naps during the 7-day period. We alo used a 
questionnaire that asked patients whether or not they experienced any sleep benefit, 
based on the recently revised definition of sleep benefit, as follows: “Sleep benefit is 
the experience of a temporary decrease in Parkinson’s symptoms upon awakening after 
a period of sleep (night or daytime), before drug intake; the patient is feeling as good as 
“on” (or better)”.
More details on both the diary and questionnaire can be found in the paper describing 
the results of these instruments [11].
We estimated a required number of subjects based on an effect size  of one-third of 
the effect size to differentiate between healthy controls and early diagnosed Parkinson 
patients [8]. With a correlation between consecutive pegboard test results of 0.93 [7], 
an α value of 0.05 and β of 0.8, this yielded a required group size of approximately 
17 evaluable subjects. We were able to include 18 Parkinson patients who clearly 
reported to experience a subjective improvement in motor functioning after night and/
or daytime sleep. In addition, we selected 20 patients who reported no improvement 
at all after sleep. 
We included patients with idiopathic Parkinson disease, defined according to the UK 
Brain Bank criteria, Hoehn & Yahr stage I-III. Exclusion criteria included current major 
psychiatric diagnosis, deep brain surgery for Parkinson disease, neurological disease 
other than Parkinson disease and chronic daily use of hypnotics. All patients were 
used to taking an afternoon nap, so they felt able to sleep during the nap period in the 
experiment.
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Healthy Controls
Twenty healthy controls participated. These controls were recruited in the older healthy 
population (40-75 years old). Controls were not necessarily habitual nappers; however, 
they all indicated that they were able to sleep during the day. Exclusion criteria were 
current neurologic or psychiatric diagnosis and chronic daily use of hypnotics.
Consent
The study was approved by the institutional medical ethical committee. All participants 
gave their written informed consent before participating. Participants received a 
financial compensation for their participation in this study.
Study Design
Procedure
Figure 1 shows the study design. In the early evening, subjects arrived at the sleep lab. 
First they were trained extensively in the pegboard dexterity task and finger tapping 
task. Before bedtime, a test session was completed (test 1). All test sessions included 
the pegboard dexterity task, finger tapping task, and subjective rating scales on motor 
functioning and mood/vigilance, described below. The order of administration was 
counterbalanced across subjects.
Subjects spent the night at the sleep lab. On awakening in the morning, a test session 
was completed (test 2). For all post-sleep measures, the tasks were administered 15 
minutes after awakening to reduce the possible influence of sleep inertia. Later in the 
morning, a neuropsychological test battery was completed. 
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Figure 1  |  Schematic overview of the study design.
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In the early afternoon, all subjects took an afternoon nap directly followed by a test 
session after awakening (test 4). We applied a crossover design, in which the reference 
examination (test 3) was done either before the nap or after an additional period of 
active wakefulness, when possible sleep benefit effects had disappeared. The order 
of examination was randomized and counterbalanced in all groups. The results of 
test 3 did not differ, either when this test was performed before the nap or after rest. 
Therefore, these data were pooled in the analyses.
At every test session the pegboard task, task switching task and motor and mood/
vigilance rating scales were obtained. During the night and afternoon nap, sleep 
was monitored by polysomnography and video. During the neuropsychological 
examination the Mini mental state examination, Frontal assessment battery, Dutch 
adult reading test, and Beck depression inventory were obtained.
Night Sleep
Subjects went to bed at 23:00 and slept until they woke up spontaneously to reduce 
the possible effects of residual sleepiness (sleep inertia) on morning testing. However, 
when not yet awake at 07:30, they were awakened by the experimenter. After 06:00, 
when a subject woke up and did not fall asleep again within 15 minutes, the night sleep 
period was terminated and post sleep tasks were started. 
Nap
For the afternoon nap, subjects had a 90-min nap opportunity. The subjects slept 
until they woke up spontaneously or were awakened by the experimenter when the 
90 min were over. When a subject slept a cumulative minimum of 15 min and did not 
fall asleep again within 15 min, the nap period was terminated and post sleep tasks 
were started. 
Rest Period
During the rest period, subjects could perform their normal afternoon activities for 90 
min. They were, for example, allowed to talk to the experimenter, read a book, or take 
a short walk, but they had to stay at the lab. Subjects were not allowed to sleep during 
the rest period.
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Medication
On the day of arrival in the sleep lab for the night of the study, patients did not take 
their Parkinson medication after 13:00. When they arrived in the sleep lab, they were 
thus already in the “off’’ state. After the pre-night test sessions, patients took their 
normal bedtime dose of Parkinson medication before the night (23:00), to increase 
the probability of a normal night of sleep. When patients did not take medication at 
bedtime, they postponed their evening medication (i.e., dinner time) to the night. This 
was the case for 10 patients (55.5%) with sleep benefit and 6 (30%) patients without 
sleep benefit. All dopaminergic medication was converted into the L-dopa equivalent 
dose (LED), using the formula described by Tomlinson et al. [12]. In the sleep benefit 
group, 16 patients were using levodopa and 9 patients (also) used dopamine agonists. 
In the group without sleep benefit, 19 patients used levodopa and 9 patients (also) used 
dopamine agonists. Both patients and controls were allowed to take other prescribed 
drugs. During the stay at the sleep lab, subjects were not allowed to drink any caffeine 
or alcohol containing drinks.
Measures
Motor tasks
In the modified Perdue pegboard task, the time needed to place eight pegs from one 
hole to the next using one hand was measured. In the finger tapping task, the number 
of taps in 30 sec and the number of errors (pressing the 2 keys simultaneously) were 
registered. These finger tapping scores were automatically converted into a number of 
cycles (Hz). Both tasks were performed with both hands separately using a computer-
based device (part of the At-Home Testing Device, Intel, courtesy of the Kinetics 
Foundation) [9]. Subjects practiced the tasks, alternating both hands, until scores 
reach asymptotic levels, with a minimum of 4 practice trials.
Subjective assessment of functioning after sleep
The symptom diary was based on the SCOPA Diary Card (SCOPA DC) [13], a validated 
instrument to assess changes in motor functioning during the day. Patients indicated 
on a 4-point Likert scale how well they could perform 3 activities, i.e., walking, 
changing position, and using their hands, a higher score indicating more difficulties in 
performance. These activities were proven to give a reliable indication of general motor 
functioning [13]. The scores on different items were added to obtain one subjective 
motor score. In addition, the question on sleep quality from the SCOPA DC was used 
and we added an extra question on feeling rested upon awakening. Mood/vigilance 
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ratings were obtained using a 16-item visual analogue scale containing 3 factors: 
alertness, calmness, and contentedness [14]. 
Neuropsychological tasks
To asses baseline neuropsychological functions, a battery of tasks was used: Beck 
Depression Inventory (BDI) [15], Mini-Mental State Examination (MMSE) [16], Frontal 
Assessment Battery (FAB) [17] and premorbid intelligence levels were assessed using 
the Dutch version of the National Adult Reading Test (DART) [18, 19].
Polysomnography
All sleep was polysomnographically monitored using a dedicated recording system 
(Compumedics Grael PSG, Compumedics, USA). PSG registration included standard 
6-channel electroencephalography and electromyography of m. submentalis. Sleep 
stages were scored according to the AASM 2007 criteria [20] using ProFusion software 
(ProFusion sleep 3 [build 392], Compumedics, USA). The main sleep outcomes were 
total sleep time, sleep efficiency, and sleep latency.
Analyses
All analyses were performed separately for night sleep and afternoon nap. The 
motor tasks and subjective measures on motor function and mood/vigilance were 
analyzed using repeated measures ANOVA, with the between-subject factor “group” 
(subjective sleep benefit, no sleep benefit, healthy controls) and one within-subject 
factor “sleep” (before sleep vs. after sleep). Sleep benefit was defined as a group by 
sleep interaction in these ANOVA models. Correlation analyses were performed using 
partial correlations controlled for “group.” Alpha was set to 0.01 in all analyses regarding 
multiple comparisons. All analyses were performed in SPSS version 20 for Windows.
Results
Characteristics of the participants, baseline motor scores, and scores on the 
neuropsychological examination can be found in Table 1. The patient groups did not 
differ from each other, except that patients with sleep benefit tended to have longer 
disease duration (t = 2.56, p = 0.015). There was a trend towards higher LED in the 
sleep benefit group (t = 2.046, p = 0.05). However, there were no between group 
differences in the proportions of patients using extended release L-dopa, dopamine 
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agonists, or COMT inhibitors. Patients had higher scores on the Beck depression 
inventory than the healthy controls (healthy controls vs. sleep benefit t = 4.84, p < 
0.001, healthy controls vs. no-sleep benefit t = 6.18, p < 0.001 ). 
The no-sleep benefit group scored slightly lower on the Frontal Assessment Battery 
(FAB) than healthy controls (t = -3.33 , p = 0.002); however, the group reporting sleep 
benefit showed no significant differences on the FAB when compared to healthy controls. 
Table 1  |  Descriptive demographics and clinical disease characteristics of study sample 
Patients Healthy controls
Sleep Benefit No Sleep Benefit
N 18 20 20
Men (N(%)) 6 (35%) 14 (70%) 11 (58%)
Age (yrs) 61.0 ± 5.9 63.2 ± 7.8 58.5 ± 7.5
Disease duration (yrs) 7.7 ± 4.3 4.6 ± 2.7 na
Age onset (yrs) 52.3 ± 7.7 57.0 ± 7.7 na
LED (mg/day) 777 ± 384 542 ± 270 na
MMSE 28.18 ± 2.2 27.75 ± 1.9 28.84 ± 1.2
FAB 16.06 ± 1.5 15.25 ± 2.3 17.16 ± 0.9
DART (IQ estimate) 111.18 ± 17.7 108.85 ± 17.5 105.84 ± 18.4
BDI 10.12 ± 6.5 8.75 ± 3.8 2.68 ± 2.4
Baseline PGT (sec) 19.5 ± 3.9 18.5 ± 3.3 14.3 ± 1.2
Baseline FTT (cycles) 75.2 ± 27.2 75.4 ± 44.7 94.2 ± 26.4
LED | levodopa equivalent dose, MMSE | Mini mental state examination, FAB | Frontal assessment 
battery, DART | Dutch adult reading test, BDI | Beck depression inventory, PGT | pegboard task,  
FTT | finger tapping task
Values indicated on Table represent Mean ± SD unless otherwise specified.
The two patient groups did not significantly differ on the presented variables, except for disease 
duration. This is in line with previous findings on sleep benefit. 
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There were no between group differences in total sleep time, sleep stages, sleep 
efficiency, or sleep latency for night sleep nor afternoon nap (Table 2). There were 
also no differences in subjective ratings of sleep quality and feeling rested after sleep 
(night sleep and nap).
Table 2  |  Sleep parameters
Patients Healthy controls
Sleep Benefit No Sleep Benefit
Night 
Total sleep time (min) 356 ± 96 366 ± 98 406 ± 44
 N1 (% of TST) 12.5 ± 16.1 8.0 ± 5.1 7.8 ± 3.8
 N2(% of TST) 48.5 ± 12.55 51.3 ± 8.7 50.2 ±11.0
 N3(% of TST) 26.4 ± 11.3 25.8 ± 10.3 24.7 ± 11.0
 REM (% of TST) 12.6 ± 8.8 14.8 ± 6.8 18.1 ± 6.1
Sleep efficiency (%) 75.4 ± 17.8 76.8 ± 18.6 83.3 ± 6.3
Sleep latency (min) 32 ± 64 25 ± 31 12 ± 10
Nap
Total sleep time (min) 46 ± 24 45 ± 26 50 ± 19
 N1 (% of TST) 19.2 ± 19.1 19.2 ± 24.1 16.3 ± 20.3
 N2(% of TST) 55.2 ± 19.7 53.3 ± 25.0 49.9 ± 21.6
 N3(% of TST) 22.9 ± 23.7 25.1 ± 25.3 30.7 ±22.3
 REM (% of TST) 2.7 ± 6.0 2.4 ± 7.4 3.0 ±6.7
Sleep efficiency (%) 58.5 ± 28.5 58.1 ± 26.1 65.6 ± 20.5
Sleep latency (min) 8.6 ± 7.4 11.6 ± 10.7 8.3 ± 8.2
TST | total sleep time
There we no significant differences between the sleep benefit and no-sleep benefit groups and 
between both of these groups and controls
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Figure 2   |  Motor task scores. 
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Motor Tasks 
The results of the motor tasks can be found in Figure 2. There was a small overall 
effect of night sleep on the pegboard task (F1,55 = 9.695, p = 0.003); subjects were on 
average slower in the morning. However, for the finger tapping tasks, there was no 
overall difference in evening and morning performance. Patients were slower than 
healthy controls on both tasks (Pegboard: F2,55 = 16.938, p < 0.001, Finger tapping: 
F2,55 = 406.5, p < 0.001). For both tasks the overnight change in performance did not 
differ between the groups (no group*sleep interaction). 
For the afternoon nap, patients were again slower than healthy controls (Pegboard: F2,55 
= 15.331, p < 0.001, Finger tapping: F2,55 = 450.3, p = 0.002). There was no significant 
main effect of sleep on both tasks, nor was there a group difference in the change in 
performance (no group*sleep interaction). There was no correlation between sleep 
time or efficiency and the difference in scores on either of the motor tasks, for both 
night sleep and the afternoon nap, nor did any of the sleep architecture measures 
show such an effect.
We did a subgroup analysis with only the 11 patients that reported subjective sleep 
benefit in both the sleep benefit questionnaire and symptom diary, hypothesizing that 
these patients had the clearest subjective sleep benefit. However, when comparing 
this subgroup with patients without subjective sleep benefit and healthy controls, this 
yielded comparable results. 
Subjective Measures
Motor Symptom Diary
Patients had higher (worse) scores in the motor symptom diary than healthy controls 
(night: F2,55 = 22.4, p < 0.001; healthy controls vs. sleep benefit p < 0.001, healthy 
controls vs no-sleep benefit p = 0.001; nap: F2,55 = 15.2, p < 0.001; healthy controls 
vs. sleep benefit p < 0.001, healthy controls vs. no-sleep benefit p = 0.01, see also 
Figure. 3). Patients in the sleep benefit group tended to have higher (worse) diary 
scores than patients in the no sleep benefit-group (night: p = 0.012 nap: p = 0.031, 
Figure. 3). We did not find a main effect of sleep on subjective motor scores after 
either night sleep or afternoon nap. There was also no group difference in the 
over-sleep change in subjective motor function (no group*sleep interaction). The 
correlation between the subjective motor score and the pegboard test, calculated 
using all available timepoints (before and after night and daytime sleep) was rp = 0.43 
(p < 0.001) and between the subjective motor score and the finger tapping test was 
rp = -0.30 (p < 0.0001).
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Figure 3  |  Subjective symptom diary scores.
Table 3  |  Subjective measures of mood/vigilance.
Sleep Benefit No Sleep Benefit Healthy Controls
Pre-sleep Post-sleep Pre-sleep Post-sleep Pre-sleep Post-sleep
Night
Alertness 4.4 ± 0.3 4.4 ± 0.3 3.5 ± 0.3 3.8 ± 0.4 2.3 ± 0.5 2.4 ± 0.3
Calmness 4.1 ± 0.6 3.5 ± 0.6 3.7 ± 0.4 3.8 ± 0.5 2.1 ± 0.4 1.9 ± 0.3
Contentedness 3.2 ± 0.4 3.2 ± 0.4 3.2 ± 0.4 3.0 ± 0.4 1.5 ± 0.2 ± 0.2
Nap
Alertness 3.7 ± 0.3 3.4 ± 0.5 3.0 ± 0.4 3.3 ± 0.4 1.4 ± 0.3 2.4 ± 0.4
Calmness 3.9 ± 0.5 3.1 ± 0.5 3.1 ± 0.4 3.0 ± 0.4 1.3 ± 0.3 1.4 ± 0.2
Contentedness 2.7 ± 0.3 2.6 ± 0.4 2.7 ± 0.3 2.7 ± 0.4 1.1 ± 0.2 1.4 ± 0.2
The possible mood/vigilance rating scores range from 0 (very alert/calm/contented) to 10 (not alert/
calm/contented at all). Results are presented as mean ± SE
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Mood/Vigilance Rating Scales
There was no effect of sleep on the mood/vigilance scales for night sleep or afternoon 
nap. There was also no group difference in the over-sleep change in mood/vigilance 
(no group*sleep interaction). The healthy controls felt better than both patient groups 
(p < 0.005 for all scales, see also Table 3); however, the patient groups did not differ. 
The mood/vigilance rating scores did not correlate with the scores on the motor tasks.
Discussion
The existence of subjective sleep benefit in Parkinson disease has been reported 
repeatedly in the literature [1-4, 21-24]. However, only few studies assessed whether 
sleep benefit is also associated with an objective improvement in motor symptoms. 
Here we used two quantitative motor tasks to assess sleep benefit in Parkinson patients. 
We showed that there was no objective sleep-related improvement in Parkinson signs 
in patients who declared to experience subjective sleep benefit. As expected, patients 
with and without subjective sleep benefit were slower on the quantified motor tasks 
than healthy controls. However, patients with or without sleep benefit did not differ in 
task performance after sleep.
We examined whether the lack of objective sleep benefit could be explained by the 
quality of the intervening sleep episodes. If “sleep benefit” is a real phenomenon, 
qualitatively better sleep should result in greater benefit for patients. Objective and 
subjective sleep quality did not differ between groups, and both nighttime sleep and 
afternoon naps were similar among groups. This shows that all groups achieved a 
good amount of sleep, excluding the possibility that lack of actual sleep explained 
the negative findings. Some studies suggested  that sleep benefit might be related 
to poorer sleep [2, 5, 25]. However, we found no support for this hypothesis. Taken 
together, our results suggest that the quality of the preceding period of sleep does not 
determine the occurrence of sleep benefit either way, at least not for the range of sleep 
qualities achieved in this experimental setting.
Patients with subjective sleep benefit may also simply feel better after sleep. However, 
we did not find differences in subjective mood/vigilance and subjective sleep quality 
among patient groups. Although there was no change in subjective motor scores after 
sleep in patients with or without subjective sleep benefit, patients with sleep benefit 
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tended to rate their motor signs as worse than patients without sleep benefit. So, the 
diary scores were not simply a reflection of mood/vigilance at the moment of testing. 
Moreover, the quantitative motor performance correlated with the subjective motor 
evaluation whereas the other subjective measures did not correlate with quatitative 
motor performance.
During the study, patients were not allowed to take Parkinson medication, so they were 
in the “off” state. We chose this approach because medication could mask possible 
sleep benefit. Furthermore, the exact influence of medication on motor functioning 
is difficult to define. Because of the large variability in medication we decided to test 
all patients without medication. There was a trend towards more medication use 
in patients with sleep benefit, so they possibly experienced a greater medication 
withdrawal effect. However, this was not reflected by the quantitative motor scores, nor 
by the the mood/vigilance scores. 
The leading hypothesis on the mechanism of sleep benefit states that dopamine 
storages in nigral neuronal terminals are replenished during sleep [2, 5, 26]. According 
to this hypothesis, the presence of sleep benefit should have been more clear without 
medication, as its effect would not be masked by dopaminergic medication. As we 
did not find an objective sleep benefit effect, this hypothesis seems less likely. It could 
also be that sleep benefit is an overnight medication effect, for example caused by 
extended release L-dopa or longer acting dopamine agonists. In our patients, there 
was a trend toward more daily L-dopa equivalent medication use in the sleep benefit 
group, but the use of different types of medication did not differ between patient 
groups. However, we acknowledge that our study was designed to assess the effect 
of sleep and not the effect of medication. Therefore, the exact influence of medication 
on (fluctuations in) motor function remains to be studied formally using a design 
dedicated to diurnal medication effects.
As sleep benefit is a temporary phenomenon [2, 4, 26], we decided not to use an 
additional clinical examination to assess Parkinson signs. When performing an 
extensive examination such as the UPDRS, possible sleep benefit effects could have 
disappeared before finishing the complete test. As the aim of this study was to assess 
differences in objective motor performance, we chose to use two quick, quantitative 
motor tests, which do correlate well with the UPDRS [7, 10].
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We evaluated only one night of sleep and one daytime nap. There could be some 
day-to-day variation in the occurrence of sleep benefit. None of the patients reported 
improvement every night in the 7-day screening diary used for recruitment. So, even 
the patients with clear subjective sleep benefit had nights without improvement in the 
symptom diary. A longitudinal study including more nights and naps could account for 
this variation. There was some variability in results; in both patient groups there were 
patients who improved and patients who worsened on the motor tasks. However, the 
individual differences in performance over sleep were small, and even in the healthy 
control group there were subjects who improved and subjects who deteriorated a 
similar amount after a period of sleep. So the observed differences in performance are 
probably not Parkinson-specific, but represent a naturally occurring effect throughout 
the population.
It was shown before that patients with subjective sleep benefit sometimes seem to 
misperceive their motor functioning at awakening. Högl et al. reported that “several 
patients with sleep benefit praised their morning mobility as unrestrained […] although 
their overall appearance and objective evaluation using UPDRS were indicative of being 
in the “off” state.” [5] Our results also showed that the subjective experience of sleep 
benefit did not match actual improvement in motor functioning. Our results combined 
with these previous findings offer further evidence that sleep benefit is mainly a 
subjective phenomenon that is not related to a Parkinson-specific improvement in 
motor function. Nevertheless, subjective sleep benefit is reported in the literature by 
a consistently high number of patients. The origin and underlying mechanism of this 
subjective sleep benefit should be the focus of future research.
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Abstract
Introduction: Upon awaking, many Parkinson’s patients experience an improved 
mobility, a phenomenon known as ‘sleep benefit’. Despite the potential clinical 
relevance, no objective correlates of sleep benefit exist. The discrepancy between the 
patients’ subjective experience of improvement in absence of objective changes is 
striking, and raises questions about the nature of sleep benefit. We aimed to clarify 
what patients reporting subjective sleep benefit, actually experience when waking up. 
Furthermore, we searched for factors associated with subjective sleep benefit.
Methods:  Using a standardized topic list, we interviewed 14 patients with unambiguous 
subjective sleep benefit, selected from a larger questionnaire-based cohort. A 
grounded theory approach was used to analyse the data.
Results: A subset of the patients described a temporary decrease in their Parkinson 
motor symptoms after sleep. Others did experience beneficial effects which were, 
however, non-specific for Parkinson’s disease (e.g. feeling ‘rested’). The last group 
misinterpreted the selection questionnaire and did not meet the definition of sleep 
benefit for various reasons.
There were no general sleep-related factors that influenced the presence of sleep 
benefit. Factors mentioned to influence functioning at awakening were mostly stress 
related.
Conclusion: The group of patients convincingly reporting sleep benefit in the 
selection questionnaire appeared to be very heterogeneous, with only a portion of 
them describing sleep benefit on motor symptoms. The group of patients actually 
experiencing motor sleep benefit may be much smaller than reported in the literature 
so far. Future studies should employ careful inclusion criteria, which could be based 
on our reported data.
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Introduction
Parkinson’s disease is a neurodegenerative disorder with motor symptoms primarily 
characterised by stiffness and slowness of movement. Many patients also experience 
non-motor symptoms such as cognitive problems, depression and sleep disorders. 
Although sleep disorders are highly prevalent in Parkinson’s disease [1], there are also 
patients who report beneficial effects of sleep. Upon awaking in the morning, many 
patients experience an improved mobility as if they are in a medication-induced 
“on” state, contrary to what would be expected after a night without medication. This 
phenomenon is known as sleep benefit [2]. Some Parkinson’s patients even state to 
delay or forget their morning dose of medication because of this sleep benefit [3, 4].
In questionnaire studies on sleep benefit, 30-55% of the patients reports to be familiar 
with the phenomenon [3-5]. One study described an improvement in clinical motor 
examination (UPDRS-III) after sleep in patients that experienced sleep benefit [6]. 
However, results from a recent study by our group on objective motor improvement 
in sleep benefit showed a different picture. We used two quantitative motor tasks to 
assess sleep benefit in Parkinson’s patients. We found no objective sleep-related 
improvement in Parkinson signs in patients who nonetheless declared to experience 
subjective sleep benefit [7].
The discrepancy between the patients’ experience of sleep benefit in absence of 
objective improvement is striking, and raises questions about the nature of the sleep 
benefit phenomenon [7]. The origin and characteristics of subjective sleep benefit are 
still unclear. Because of the use of closed-end questions in previous sleep benefit 
research, it is not known what kind of improvement patients refer to when they report 
sleep benefit. It seems reasonable to make a distinction between 1 | a subjective 
general feeling of improvement after sleep and 2 | a specific improvement in actual 
motor functioning, as probably both are perceived as sleep benefit by Parkinson’s 
patients [4]. More insight in the subjective experiences of patients who report sleep 
benefit, could be key in understanding this phenomenon.
Qualitative research methods provide a powerful tool for a more profound 
understanding of subjective experiences [8-10]. We performed a qualitative interview 
study to obtain more insight in what patients who report sleep benefit, experience 
when they wake up. Furthermore, we aimed to identify the factors that may influence 
the self-reported sleep benefit.
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Methods
Subjects 
A flow chart of the inclusion process can be found in figure 1. Patients were recruited 
from a cohort of 237 patients that participated in a previous questionnaire study on 
sleep benefit [4]. In this questionnaire the following definition/explanation of sleep 
benefit was used: Sleep benefit is the experience of a temporary decrease in Parkinson’s 
symptoms upon awakening after a period of sleep (night or daytime), before drug intake; 
the patient is feeling as good as “on” (or better) [11]. 
For this study we only selected patients that reported sleep benefit in the questionnaire 
(N = 74). Furthermore, the open-end question in which patients gave a description of 
their morning experience was leading in the selection: we invited patients who, based 
on their own description, were –in our clinical view- most probable to experience 
some sort of sleep benefit. Patients giving a description indicative of misunderstanding 
the definition of sleep benefit given in the questionnaire were not invited. Inclusion of 
patients and initial coding of the interviews were performed in parallel. New patients 
were included until data saturation was reached and no more new codes emerged 
from the interviews. In total, information letters about the study were sent to 16 patients. 
These patients were contacted by telephone to provide general study information 
and - when interested - to book an appointment for the interview. After telephone 
consultation, all patients agreed to participate. 
We included patients with idiopathic Parkinson disease, defined according to the 
UK Brain Bank criteria, Hoehn & Yahr stage I-IV. All patients were fluent in Dutch. 
Exclusion criteria included current major psychiatric or cognitive disorders. The study 
was approved by the institutional medical ethical committee (file no. 2014-1355). All 
participants gave their written informed consent before participating.
Interviews
For the semi-structured interview with open questions, we used an interview guide. 
Initially the interview guide only contained a few very wide scoped questions. Patients 
were invited to tell everything they considered relevant, without steering them into a 
certain direction. 
Patients were asked how they experienced their symptoms at waking up. Both 
night sleep and daytime naps were evaluated. Questions on day-to-day variation in 
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functioning gave more insight in factors that could influence sleep benefit. Later in the 
series we added more focussed questions on various specific Parkinson symptoms 
and aspects of sleep quality. Probing questions were used to follow up whenever 
necessary. The interviews took place at the patient’s home. Interviews lasted about 
30-45 minutes and were recorded and later transcribed verbatim by the interviewer. 
The interviewer (ICC) was trained and experienced in taking interviews. She was new 
to the field of sleep benefit, as such she was open to whatever the patients presented 
and had no preconceptions about the phenomenon. 
Analyses
A grounded theory approach was used to analyse the data [8]. The interviews were 
read and re-read to become familiar with the data. Initial open coding was performed 
by two researchers (MvG and ICC) independently to increase reliability. All codes were 
compared and contrasted until consensus was met. This was followed by an axial 
coding process, in which codes were sorted and classified into recurring themes. All 
researchers from the multidisciplinary team were involved in the development of the 
final thematic structure. Generally, differences in interpretation between researchers 
were small and consensus was rapidly achieved. All ideas and questions that were 
raised during the analytical process, were registered in memo’s. A computer software 
package, Atlas.ti (version 7), was used to manage the data.
Results
A total of 14 patients (5 men, 36%) were included in the analyses (Figure 1). One 
interview was cancelled because the patient was admitted to the hospital. Another 
interview was excluded because the patient had surgery for deep brain stimulation 
(DBS) and did not experience any Parkinson symptoms ever since. She could not 
remember much about her symptoms at waking up before the DBS, i.e. the time she 
completed the inclusion questionnaire.
Age of the patients ranged from 55 to 75 years (mean 61 yrs). Disease duration 
(from onset of first symptoms) ranged from 5 to 30 years (mean 13 yrs). All patients 
used dopaminergic medication; 13 patients used L-dopa and 8 patients (also) used 
dopamine agonists.
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Figure 1  |  Flow chart patient inclusion
yes
no
163 patients without sleep benefit
• 1 interview cancelled (hospital admission)
• 1 interview excluded (no memory of sleep
   benefit since DBS surgery)
237 patients completed
sleep benefit
questionnaire
74 patients
with sleep benefit
One-by-one
inclusion and coding
Saturation reached?
14 patients
included in analyses
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After coding of the data two central themes emerged. 1 | Experiences at waking up, 
which could be divided in the sub-themes physical functioning and mental functioning 
and 2 | Factors that influenced functioning at awakening, which included sleep related 
factors and other factors.
Experiences at waking up
When patients told about their experiences at waking up, these could be divided 
into two sub-themes; physical functioning and mental functioning, in which patients 
described their physical/mental abilities at waking up. Both sub-themes had ‘positive’ 
and ‘negative’ categories, containing codes that indicated functioning that was notably 
good at awakening or -in contrast- functioning that was affected by the Parkinson’s 
disease. The physical theme contained codes for different kinds of actions and 
symptoms, such as getting out of bed, walking and tremor. In the mental theme we 
identified codes for different aspects of mental functioning, such as feeling relaxed, 
feeling rested and feeling energetic.
Based on the co-occurrence of different codes within this theme, we distinguished 
three interpretations of sleep benefit: 1 | patients that described motor sleep benefit 
(n=6), 2 | patients without sleep benefit (n=5) and 3 | patients that experienced 
unclassified sleep effects, i.e. some sort of improvement that was not clearly sleep 
benefit (n=3).
Motor sleep benefit 
The six patients in this group clearly described a decrease in Parkinson-specific 
motor symptoms. At waking up they find it easier to perform all sorts of movements, 
such as getting out of bed, walking, getting dressed, writing and household tasks. 
Furthermore, some patients experienced less tremor and freezing of gait.
“I just get out of bed and walk. I don’t have to sit on the side of the bed first, I can get 
up without effort.” (P5, night)
“Yes, then my handwriting is fine, however that expires within half an hour, then it’s 
over.” (P6, night)
“the first half hour in the morning, I would describe it as feeling ‘on’” (P6, night)
“But the tremor, I don’t feel, I don’t have it when I wake up” (P14, night) 
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“Well, I go to the kitchen for example, and it is easy to clean the countertop, or eh, 
to make sandwiches, that kind of things. And I do not stick to the ground.” (P1, nap)
 
Although moving was easier, most of these patients did experience stiffness when 
getting out of bed.
“Getting dressed is easier, but walking is stiff. Tasks in the kitchen are trouble-free” 
(P1, night) 
“I feel a little stiff, but that’s it. In the morning I’m at my best” (P4, night)
Patients with motor sleep benefit described a clear limited duration of the effects, 
ranging from thirty minutes to two hours. All patients experienced an improvement 
in motor functioning after night sleep. Some patients also reported motor benefit of 
an afternoon nap or when waking up during the night. Many patients also reported a 
mental benefit of sleep, mostly in terms of ‘feeling well rested’.
No sleep benefit 
These five patients did not meet the definition of sleep benefit for various reasons. For 
example, some patients experienced many symptoms at awakening. Therefore, they 
took their morning medication in bed and waited in bed until it started working. The 
described ease with getting out of bed was clearly a medication effect rather than a 
sleep effect. Other patients needed their medication at waking up, however, overall 
they felt better in the morning than in the afternoon. There was also a patient who 
described that a good night of sleep was very beneficial for functioning during the 
whole next day. So the effect was not specific for the first moments after waking up, but 
rather an all day ‘bonus’ that worked on top of the normal medication.
Unclassified sleep effects 
There were three patients that did not fit in either the motor sleep benefit or the no 
sleep benefit group. These patients reported to feel good at waking up. However this 
improvement mostly seemed to be a mental rather than a physical change. Patients 
described feeling relaxed, energetic, clear headed or peaceful. This state of mind was 
reflected in overall functioning, but Parkinson specific motor symptoms were present 
explicitly at awakening.
99
6 |  Grounded theory study on sleep benefit
6
“That is not really a physical thing, but in my head, I feel really relaxed. Whatever 
happens, I just let it happen without fighting it. So there is more comfort in my body 
maybe. I don’t worry so much or think ‘whatever’. And then I am able to get up 
calmly.” (P2, night)
“Yes, yes, my body is relaxed, it feels very pleasant, a positive feeling. It has 
something to do with mood. That’s the biggest difference, when you feel relaxed, 
your body, your mood is ten times better. That is the largest benefit.” (P2, night)
“It is like calmness comes into your body, relaxation in your head. And I am a busy 
bee, but then it is just, I can let everything go. Like recharging, I feel invigorated.” 
(P8, nap)
“See, before I take a nap, I’m exhausted, especially in my head. I close my eyes and 
fall asleep immediately . Well, if I’m tired, my whole body, everything is difficult. But 
when I wake up I feel as fit as a fiddle so to say (laughs), then it’s just fine.” (P9, nap)
In this group, the described beneficial effects of sleep could occur after night sleep, an 
afternoon nap or both. The benefit started at the moment of waking up, however, these 
patients did not indicate a clear duration of the phenomenon. 
One patient took her medication in bed and slept until the medication started working. 
Sometimes she woke up feeling exceptionally good. Other mornings getting out of 
bed was very troublesome. 
“Well, when I wake up feeling relaxed, taking a shower is easier. I can just move 
more easily. [...] And when I don’t wake up feeling relaxed, when I start stiffening, 
that uncomfortable feeling, then washing myself is difficult.” (P9, night)
Factors that influenced functioning at awakening
Influence of sleep factors
There was large variation in self-described sleep quality between patients. We could 
not identify any concurrent patterns in the different sleep benefit groups. Notably 
almost all patients described to experience REM sleep behaviour-like symptoms, such 
as vivid dreaming, (violent) movements and speech during sleep.
Some patients reported factors that could influence the magnitude of the beneficial 
effects of sleep. Total sleep duration, number of awakenings, presence of vivid dreams 
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and bedtime were mentioned. However, there were also patients who denied the 
influence of these factors or were not aware of any contributing factors at all.
Some patients experienced the same amount of motor benefit after an afternoon nap 
as after a night of sleep. Others reported to benefit from a nap as well, but to a lesser 
extent. Some patients mentioned that this could be because naps have a shorter 
duration. Only a number of patients experiencing unclassified sleep effects had more 
benefit of a nap than of a night of sleep. 
Other factors
Many patients, both with and without sleep benefit, described a negative influence of 
stress on their symptoms at waking up. If they had an appointment in the morning and 
had to hurry through their morning rituals they felt less comfortable and experienced 
more Parkinson’s symptoms.
On the other hand, there was also one patient that praised the silence of the night as 
the best influence on his symptoms: 
“Yes, the difference is that there is nothing around me. It’s dark, there is nobody 
there, nobody active and I can just without any, anything around me, there is no 
disturbance. [...] no influence from outside, that’s easier.” (P2, night)
Some patients described that not only sleep or a nap had positive effects, but also 
taking rest, without sleeping could reduce tremor or give more energy.
Discussion
In this grounded theory study, we interviewed patients with self-reported sleep 
benefit about their functioning at waking up and about the factors that could influence 
their abilities at awakening. We showed that some, but certainly not all, patients with 
self-reported sleep benefit experience a temporal decrease in their Parkinson motor 
symptoms. Several patients did not meet the definition of sleep benefit at all. Others 
experienced beneficial effects of sleep, however, not a specific decrease of motor 
symptoms. There were no general sleep related factors that influenced the presence of 
sleep benefit. Other factors that were mentioned to influence functioning at awakening 
were mostly stress related.
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For this study we selected patients that, by all available means, were likely to experience 
sleep benefit, selected from a large cohort of patients that reported sleep benefit in a 
questionnaire. Surprisingly, a substantial part of the interviewed patients did not meet 
the definition of sleep benefit, that was presented in the questionnaire, for various 
reasons. In all these cases, patients did not take into account a crucial part of the 
definition of sleep benefit. They mainly disregarded the statement that sleep benefit is 
experienced before the intake of medication or that sleep benefit is a temporal effect, 
specific for the moment of waking up. 
In previous studies on objective motor improvement in patients with sleep benefit, 
questionnaires were used for the selection of patients [6, 7]. Our data show that this 
inclusion method may result in a very heterogeneous group of participants. Probably 
patients without sleep benefit or with unclassified sleep effects participated in those 
studies as well. This may –in part- explain why no motor effects of sleep benefit have 
been found. It would be interesting to study whether patients with self-described 
motor sleep benefit show objective motor improvement after sleep. Our data show 
that the careful inclusion of patients in such a study is very important. Based on these 
interviews we could not find differentiating factors for motor sleep benefit. In future 
studies an extensive interview will be the best way to distinguish patients with sleep 
benefit from those without.
Three patients did not describe classical motor sleep benefit. However, they did 
experience some beneficial effects of sleep, mostly mental benefit. The mental 
improvement described by these patients was not a Parkinson specific effect of sleep, 
but rather a subjective general feeling of improvement. It could be argued whether 
this should be regarded a form of sleep benefit. For these patients, it directly benefited 
their coping with the disease. Therefore, we think that also this phenomenon could be 
clinically interesting, but the underlying mechanisms are probably different from motor 
sleep benefit. So, it is important to make a clear distinction between both phenomena.
We could not find sleep related factors that clearly influenced the occurrence of 
sleep benefit. Some patients did experience a relation between sleep quality and the 
amount of sleep benefit, however, there were large individual differences. Based on 
the small number of patients with motor sleep benefit in this sample, we cannot draw 
conclusions on this matter.
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The other factors that patients described that influenced their functioning at waking up 
were not specific for sleep benefit. Factors such as stress were also considered disabling 
during the rest of the day and are often reported by Parkinson’s patients [12]. On the 
other hand, some patients described feeling relaxed, peaceful or clearheaded after 
sleep, as if sleep had a stress reducing effect. In fybromialgia and rheumatoid arthritis, 
good sleep has a beneficial effect on coping with stressful events [13]. So, maybe in these 
cases sleep does not have a direct effect on functioning, but the effect is mediated by a 
reduction of stress or negative affect. Some patients also described beneficial effects of 
taking rest, without sleeping. This could have a stress and fatigue reducing effect as well.
In studies on objective motor function in sleep benefit, patients had to perform motor 
tasks directly at waking up [6, 7]. This could have been consciously or unconsciously 
stressful for the participants. At least the experimental setting differed from their 
standard morning routine, which many patients considered important in this study. 
This could have contributed to the lack of motor effects found in the quantitative 
studies on sleep benefit. 
Notably, many patients, also amongst those with motor sleep benefit, described 
feeling stiff at waking up. However, as some patients added, this could also be a 
general sign of aging instead of a specific Parkinson symptom. Some patients noted 
the same stiffness at waking up with their spouses, who were not diagnosed with 
Parkinson’s disease. 
For some patients it was difficult to find the exact words to describe their functioning 
at awakening. To help these patients, the interviewer asked probing questions on 
morning routines and activities. Especially on highly subjective topics, such as mental 
benefit, interpretation of the statements was not always unequivocal. Nevertheless, 
these interviews provided very divergent and exemplifying stories that could have not 
been retrieved using standardized questionnaires.
In conclusion, we showed that not all Parkinson’s patients with self-reported sleep 
benefit do experience a specific reduction in motor symptoms after sleep. The group 
of patients convincingly reporting sleep benefit in a questionnaire turned out to 
be very heterogeneous, with only a portion of the patients describing motor sleep 
benefit. Although the results of qualitative research cannot be generalized to the 
whole Parkinson’s population, it seems probable that the group of patients actually 
experiencing motor sleep benefit is far smaller than thought so far, based on previous 
questionnaire studies.
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Abstract 
This chapter presents the design of a future study on sleep benefit. The methodological 
choices are based on our previous experience with sleep benefit, as described in this 
thesis.
Rationale: A substantial proportion of Parkinson’s patients experience sleep bene-
fit; i.e. an improved mobility upon awakening. However, the relationship between the 
subjective experience of sleep benefit and objective mobility upon awaking could not 
be established using quantitative motor test in the sleep laboratory. To further explore 
this, we will use an innovative method to objectively assess motor performance longi-
tudinally in the home situation. 
Objective: The aim of this study is to explore whether subjectively experienced sleep 
benefit can be objectively assessed using computer vision based analysis of motor 
performance upon awakening. Secondarily, patient experiences and data quality of 
the assessment method will be gathered. 
Study design: A cross-sectional study with a 4 week follow-up will be performed. Pa-
tients will have a video camera, that will record from one hour before until one hour 
after awakening, installed in their bedroom during the 4 week follow-up period. 
Study population: 30 patients, diagnosed with Parkinson’s disease (H&Y stage I-III) 
will be included: 15 patients indicating to experience sleep benefit and 15 patients in-
dicating not to experience sleep benefit, based on an extensive telephone interview. 
Main study parameters/endpoints: Spatiotemporal and kinematic data (such as 
walking speed, joint angles, step length, arm swing etc) will be automatically extracted 
from the video registration. Parameters extracted have been shown to be related 
to diagnosis and disease progression. However, on forehand we do not know what 
parameters will be indicative of sleep benefit and we will therefore apply a hypothesis-
free approach. 
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Introduction
Parkinson’s Disease is a neurodegenerative disorder characterized by motor as well 
as non-motor symptoms. Motor symptoms include bradykinesia, postural instability, 
freezing and tremor [1]. Sleep disorders are part of the common non-motor symptoms 
[2]. However, also a substantial proportion (30-55%) of the Parkinson’s patients reports 
favourable effects of sleep, known as sleep benefit [3].  At awakening in the morning, 
they experience improved mobility as if in the medication induced ‘on’ state [4-6]. 
Up to 21% of the patients that reported sleep benefit, indicated that they could delay 
or even skip their morning medication because of sleep benefit [4]. Most studies on 
sleep benefit evaluated outcomes based on subjective patient experiences using 
questionnaires or symptom diaries [4, 6-12]. The relationship between this subjective 
experience and objective motor performance is, however, not clear [13]. Because of 
day-to-day variation in the occurrence of sleep benefit, longitudinal assessment of 
sleep benefit using objective and accurate measures is highly needed [12, 14]. 
Many instruments to assess mobility in Parkinson’s disease have been developed. 
The Unified Parkinson’s Disease Rating Scale (UPDRS) – III (motor subscale) is an 
extensive tool to quantify mobility in Parkinson’s patients. Moreover, it is often used 
clinically to classify disease progression [15, 16]. The UPDRS-III, however, is based on 
the subjective rating of the observer and is time consuming. More objective mobility 
measures include for example the Timed Up & Go Test, the Pegboard Dexterity Test 
and Finger Tapping Test which show good correlations with UPDRS-III score [17, 18]. In 
addition, an increasing number of spatiotemporal and kinematic parameters of gait and 
postural control are being identified that distinguish Parkinson’s patients from healthy 
controls and can discriminate between different stages of Parkinson’s disease severity 
[19-22]. For example, gait speed, stride length, cadence, joint angles, arm swing and 
trunk rotation. These parameters can be accurately assessed in movement labs using 
advanced registration systems or using body worn sensors such as accelerometers. 
Application in the patient’s home environment to longitudinally assess mobility and 
possible effects of sleep benefit, however, is limited. 
A recent study that used the Pegboard Dexterity Test and the Finger Tapping Test as 
quantitative measures of sleep benefit, did not show an objective motor effect of sleep 
in patients that experience sleep benefit [23]. This study was performed in a clinical 
setting based on one regular night sleep and one afternoon nap. Based on these 
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results, it is not clear whether sleep benefit could not be objectively confirmed because 
of the lack of adequate measurement instruments or, it should be concluded that sleep 
benefit is a subjective phenomenon. To further explore this, we will use an innovative 
method to objectively assess motor performance longitudinally in the home situation 
as an indicator of sleep benefit in Parkinson’s patients. This new method consists 
of a computerized vision based analysis system (video) that objectively measures 
spatiotemporal and kinematic characteristics of daily movements (without having to 
wear sensors). Advantages of this method are: 1 | Objective and accurate assessment 
of motor performance; 2 | Application in the patient’s home situation; 3 | Allows for 
longitudinal assessment; 4 | Minimally invasive; without having to wear sensors or 
perform ‘tests’; 5 | Being able to quantify spontaneous movements and normal/daily 
movement patterns. Besides application in the current sleep benefit study, this method 
has great potential as an outcome measure in clinical trials and could be valuable in 
daily clinical practice, providing feedback on disease progress and treatment response 
to the treating physician. 
In this chapter we present  the design of a future study on sleep benefit. The 
methodological choices are based on our previous experience with sleep benefit, as 
described in this thesis.
The aim of this study is to explore whether sleep benefit can be objectively assessed 
using computerized vision based analysis of motor performance at awakening. 
Furthermore, we aim to explore the quality of the data gathered through video 
registration in the home situation and we will evaluate the experiences of patients with 
video registration in the bedroom during the morning.
Methods
Subjects
The study population will consist of 30 Parkinson’s patients. Inclusion criteria are: 
Idiopathic Parkinson’s disease, diagnosed by a neurologist according to the UK Brain 
Bank criteria, H&Y stage I-III and being able to walk at least 10 meter independently. 
Exclusion criteria are: Cognitive impairment (MMSE<24) and neurological disorders 
other than idiopathic Parkinson’s disease.
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Because of the explorative character of this study no sample size calculation has been 
performed.
Study design
We will perform an observational, cross- sectional study in 30 Parkinson’s patients 
(figure 1). Based on a telephone interview we will classify participating patients as: 
1 | Clearly experiencing sleep benefit; 2 | Clearly not experiencing sleep benefit.
We aim to include 15 patients in both groups. A video camera will be placed in the 
bedroom of the participating patients for a 4-week period. The camera will record the 
morning ritual including getting up from bed and walking from the bed to the bedroom 
door. From the video material, spatiotemporal and kinematic parameters of getting up 
and walking will be extracted as indicators of motor performance. The camera will 
record only from one hour before waking up (normal wake up time as indicated by 
the patient) until one hour after waking up. Moreover, it will be possible for patients to 
turn off the camera at any moment or delete video material. During the 4-week period, 
patients will keep a diary considering sleep time, sleep quality and whether or not they 
subjectively experienced sleep benefit. At the end of the 4-week period, patients will fill 
in a questionnaire about their experiences with the video system. Motor performance 
during both ON and OFF state will serve as reference values. The reference activity is 
standing up from the bed and walking to the bedroom door.
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Figure 1  |  Study design
Telephone interview: 
1 | Eligibility check
2 | Classifying patient in one of the 2 subgroups
 
 
Home visit:
Home visit:
 
1 | Informed consent
2 | Installing camera in bedroom 
3 | Filming reference activity in OFF medication state
 
 
 
  
 
 
4-week period:
1 | Camera in bedroom filming
1h before  until 1h after
waking up: daily
2 | Keeping a diary: daily
  
 
 
1 | Filming reference activity in ON medication state
2 | Questionnaire on patient experiences
 
   
 
Telephone check-up
after 2 weeks
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Study procedures
Patients who participated in a former sleep benefit study [24], and indicated to be 
willing to participate in future research, will be sent information on this study. In addition 
patients will be recruited from the neurology department at Radboudumc. Patients will 
be informed about this study during their regularly scheduled visit to the neurologist 
and will be asked if they want to receive additional information on this project. In 
addition, patients who visited the neurology department in the past and indicated to 
be willing to participate in research, but who do not currently participate in a study, 
will be sent an information letter. Two weeks after sending this information, they will 
be called by a member of the research team who checks eligibility and performs 
a telephone interview on sleep benefit. Based on this interview, patients are being 
classified as: 1 | Experiencing sleep benefit;  2 | Not experiencing sleep benefit. We aim 
to include an equal number (n=15) of patients in both groups meaning that patients 
will be excluded when the group in which they are classified has reached a maximum 
of 15. When eligible and willing to participate, an appointment for a home visit to install 
the camera will be made. At the home visit, first, informed consent will be signed: both 
for participating in this study and for approval of video registration. On the morning of 
the camera placement, patients are instructed not to take their Parkinson medication 
(≥8h without medication). During the installation, participants are asked to perform 
the activity “get up from bed and walk to the bedroom door” in ‘off’ medication state 
a number of times in order to: 1 | Check the appropriate position of the camera in the 
bedroom; 2 | collect reference data of the activity under study. The camera will stay in 
the bedroom for 4 weeks. During this period, a diary will be kept in which sleep time, 
sleep quality and experienced sleep benefit is registered. In addition, a member of the 
research team will call the participant after 2 weeks to check up on the process. At the 
final home visit, after 4 weeks, the patient is asked to perform the reference activity (get 
up from bed and walk to the bedroom door) again a number of times, but now in the 
‘on’ medication state. Finally, the patient is asked to fill in an evaluation questionnaire 
considering their experiences with daily camera monitoring in the bedroom. At the 
end of the home visit, the camera is removed from the bedroom.
Telephone interview
An extensive interview can be a useful tool to determine the presence of sleep benefit. 
In the telephone interview, patients will be asked how they experience their Parkinson’s 
symptoms at waking up. Questions on morning routines and activities are used to get 
more insight in the presence of sleep benefit. Patients will be classified in 2 groups:
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1  |   Clearly experiencing sleep benefit: this are the patients who explicitly report an 
improvement of motor functioning. They for example mention to walk better after 
awakening or having less trouble taking a shower or getting dressed.  NB patients 
that report to feel good after sleep ( e.g. rested, refreshed or relaxed), but do not 
report specific improvement in motor function, will not be selected in this group. 
2  |  Clearly not experiencing sleep benefit: these patients do not indicate any benefit 
from sleep.
Video registration
In this study, we will use a KinectTM second generation sensing device (Microsoft 
Corporation, Redmond, WA, U.S.A.) which incorporates a high definition colour camera, 
an infrared camera, a depth sensor and 4 microphones. The device is able to register 
colour, infrared and depth videos which will be stored on an offline computer. The 
Kinect system is shown to be able to accurately measure clinically relevant movements 
in Parkinson’s patients [25, 26].
For acquiring the videos we will place the device in the subject’s home on a wall, a 
closet or shelf in such a manner that the device will not hinder normal traffic in the 
room. Because of privacy reasons the camera will not register throughout the day. 
Registration will automatically start one hour before waking, as indicated by the patient 
and will automatically end one hour after waking. Patients have the possibility to turn off 
video registration at any time. They can also indicate that they do not want to be filmed 
the next morning; in that case the video registration will not start. Moreover, patients 
will be able to delete specific scenes. Data is initially being stored at a local hard disk 
connected to the Kinect at the patients house. No data will be transferred via the internet 
nor will it be shared with other parties. The stored videos will be made anonymous so 
that the subject’s privacy is preserved. The locally stored data will be transported to 
Radboudumc Nijmegen by the researcher performing the final home visit.
Video analysis algorithm
The video analysis algorithm is based on the body part tracking algorithm that is a core 
component of the Kinect platform [27]. This algorithm makes a 3D prediction of body 
part locations based on dept-images. 31 different body parts are labeled, including all 
major joints. Once the anatomical regions are known, a schematic skeleton is drawn 
connecting the major joints. Based on this simplified skeleton, parameters of interest 
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can be derived in 3D space. For example stride length, gait speed, cadence, joint 
angles, arm swing and trunk rotation. These parameter values are registered in a list 
from which plots can be drawn for later clinical evaluation. Additionally, we visualize the 
detected points of interest and the measured parameters on the input video, to get an 
intuitive view of the measured parameters and their temporal dynamics. 
Figure 2  |  Processing steps of the Kinect system
A | video image, B |  Dept image, C | Detected body, D |  Prediction of body parts and major joints
A| B|
D|C|
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Study parameters/endpoints
Main study parameter/endpoint
Spatiotemporal as well as kinematic data will be extracted from the video registration. 
Certain points of interest like joints and body parts extremities (foot, hands) will be 
identified in the  video sequences. Further, based on the tracked points and body parts 
distances, angle and  time will be calculated to derive the clinical parameters (step 
length, arm-swing angle, “timed up and go”, etc.). All these data will be registered in 
lists of values and charts. The parameters that will be extracted have been shown to 
be related to Parkinson’s disease diagnosis and disease progression, including: time 
to perform sitting to standing, walking speed [18, 19],  stride length [19, 28], cadence 
[20], arm swing [29], joint angles (knee, ankle and pelvis) [28], and trunk rotation [29]. 
We will apply a hypothesis-free approach; on forehand we  do not have a hypothesis 
about what parameter will be most indicative of sleep benefit. 
Secondary study parameters/endpoints 
Secondary study parameters include subjectively experienced sleep benefit, sleep 
time, sleep quality, patient experiences with video registration in the bedroom and 
quality of the data gathered. Data quality will be judged based on the amount of 
analyzable data. Of the 28 mornings that will be recorded, there should be analyzable 
data recorded on at least 10 mornings. Factors that may influence this are time the 
patient spends moving in front of the camera and the number of individuals that 
are simultaneously present in the camera’s view. The more time is spent in front of 
the device, the more clinically relevant information can the software extract from the 
acquired videos. 
Finally, at the end of the study, patient opinions will be explored using an evaluation 
questionnaire. Patients will be asked about their experience with having a camera in 
their bedroom for a prolonged period of time. Mainly questions about privacy issues, 
preferred user options (turning on – off etc) and design will be asked. The results of the 
questionnaire are extremely important for future developments in this field.
Statistical analysis
In the sleep benefit group, within subject comparison will be made comparing motor 
functioning on mornings when a patient experienced sleep benefit (as indicated in the 
diary) with motor functioning on mornings when a patient did not experience sleep 
benefit (as indicated in the diary). In addition motor functioning on the morning on 
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which patients experience sleep benefit will be compared to motor functioning in both 
‘on’ and ‘off’ medication state. Analysis will be done for all spatiotemporal an kinematic 
parameters gathered upon awakening. We do not know in advance which of the 
parameters will be able to discriminate between these states or objectively measure 
sleep benefit, therefore we do not have hypotheses about the expected differences on 
forehand. 
Secondarily we will compare motor functioning between groups; the difference 
between motor functioning upon awakening and motor functioning in OFF medication 
state will be compared between groups. 
Discussion
With this study we aim to objectively assess sleep benefit using computerized 
vision based analysis of motor performance at awakening. Previous studies were 
based on only one night or nap or used subjective assessment of sleep benefit in a 
questionnaire or diary. This technique allows for longitudinal assessment in the home 
environment.  Another advantage for the patient is that it is not necessary to wear 
sensors. Furthermore, no particular tests or tasks have to be performed. This allows 
the analysis of natural daily movements instead of cued behaviour. 
We have selected several spatiotemporal and kinematic parameters that all have been 
shown to be related to Parkinson’s disease diagnosis and disease progression. On 
forehand we do not have a hypothesis which parameter will be most indicative of the 
presence of sleep benefit. This will also depend on the activities performed in front of 
the camera and the quality of the gathered data.
This study does not only have the potential to give more insight in sleep benefit. The 
advanced vision based analysis technique has great potential in clinical settings as 
well. This study will give more insight in the patients’ experience with the presence of 
a camera in the home environment. This user experience information is important for 
further development of the system. 
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When one first hears the term “sleep benefit”, it is easy to imagine what kind of 
phenomenon this could be. We all know the pleasant feeling of waking up after a 
good night of sleep, feeling well rested, and ready to start the new day. However, the 
descriptions of sleep benefit  by Parkinson’s patients appeared to extend beyond this 
generally refreshed feeling. Specifically, patients reported that the motor symptoms of 
Parkinson’s disease could improve drastically after a period of sleep. This raised the 
question among clinicians and sleep scientists whether sleep has revitalizing qualities 
that could even have therapeutic effects. In this thesis, we studied the phenomenon 
of sleep benefit thoroughly, from several perspectives and by employing diverse 
methodological approaches. 
Definition of sleep benefit
When we started our research on sleep benefit, this subject had not been studied for 
over a decade. One of our first efforts was to create a new definition of sleep benefit 
(Chapter 3). We noticed large differences in previous studies in definitions that had 
been used [1-7]. This could in part explain the differences in characteristics of sleep 
benefit found across the different studies. In some studies the definition of sleep 
benefit was very broad, and could easily be confused with the a-specific feeling of 
refreshment after sleep. Therefore, we stated our new definition as specific as possible: 
Sleep benefit is the experience of a temporary decrease in Parkinson’s 
symptoms upon awakening after a period of sleep (night or daytime), before 
drug intake; the patient is feeling as good as “on” (or better).  
We proposed to define the (amount of) improvement as “feeling as good as ‘on’”, i.e. 
as if the medication is working. This points out that sleep benefit reflects a specific 
decrease in Parkinson’s symptoms. By using the relative reference of  the medicated 
‘on’ state we also aimed to account for individual differences. 
We stated the definition in subjective terms, because at that time objective correlates 
of the phenomenon had not been studied sufficiently. The experience of patients was 
decisive in determining the presence of sleep benefit. We suggested to add objective 
characteristics of sleep benefit to the definition, as soon as they would become 
available. However, no additional defining features have been found to date. The new 
research on sleep benefit posed no necessity to change the subjective definition of 
sleep benefit either.
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The new definition was not only designed for clinicians and sleep scientist to recognize 
sleep benefit. We also used it in a questionnaire where patients had to report 
whether they experienced sleep benefit according to this definition (Chapter 4). For 
this particular use by patients, the new definition might have been too complex. In 
the interviews with patients who reported to experience sleep benefit based on our 
definition, a substantial part could not be classified as having sleep benefit (Chapter 6). 
In all these cases, patients did not take into account a crucial part of the definition. They 
mainly disregarded the statement that sleep benefit is experienced before the intake of 
medication or that sleep benefit is a temporal effect, specific for the moment of waking 
up. As long as the subjective patient opinion is leading for determining the presence of 
sleep benefit, a structured interview would be a better instrument than a questionnaire. 
During an interview there is more room to verify the patients’ statements and to check 
whether the questions are fully understood.
Subjective versus objective sleep benefit
Throughout our studies on sleep benefit we made a distinction between subjective 
sleep benefit (the experience of improvement upon awakening) and objective sleep 
benefit (actual improvement in motor functioning upon awakening). Initially, this 
difference in denomination was based on the type of methodology that was used to 
assess the phenomenon. However, in our detailed quantitative motor study (Chapter 5) 
we found no objective motor improvement in patients who reported to experience 
(subjective) sleep benefit. This raised the question whether sleep benefit could be a 
merely subjective phenomenon.
Feeling rested at awakening is an important property of a good night of sleep. This 
becomes particularly clear when sleep is perceived as non-restorative, for example in 
insomnia or chronic fatigue syndrome [8, 9]. This subjective feeling at awakening is not 
necessarily related to objective sleep parameters, used to determine the quality of the 
preceding period of sleep. In a recent study, good sleepers, non-restorative sleepers 
and sleep experts discussed the properties of restorative and non-restorative sleep 
in focus groups. [10]. The emerging themes associated with a good night’s sleep 
included awakening feeling rested and energetic, physically better and healthier 
and clearer minded with a sense of refreshment. Possibly this subjective feeling of 
(physical) restoration can be so strong that it can even the Parkinson’s symptoms 
seem to decrease.
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In the extensive interviews on sleep benefit, many patients described a similar mental 
benefit of sleep (Chapter 6). At awakening they felt relaxed, energetic, clearheaded and 
peaceful. The patients described that this mental state affected their overall functioning 
and coping with the disease. This effect does not seem to be specific for Parkinson’s 
disease. Possibly a similar effect can be found in other (chronic) diseases. A qualitative 
study including other patient groups, for example patients with rheumatoid arthritis, 
might give more insight in variation in coping and disease perception after awakening. 
In the interview study, there were also patients who described a very specific 
improvement of motor functioning. Whether this is a different, Parkinson-specific 
effect or a consequence of the subjective feeling of restorative sleep should be studied 
further, for example with the study design proposed in chapter 7.
In this thesis we focused on sleep benefit in Parkinson’s disease. In the review 
 (Chapter 3) we briefly discussed the possibility to study sleep benefit in other diseases. 
The specific improvement in motor function might also be found in other disorders 
such as episodic ataxia [11] or hereditary progressive dystonia [12, 13]. Only a few, rare 
cases have been described, but it could be interesting to study possible similarities with 
sleep benefit in Parkinson’s disease. First the phenomenology of these cases of sleep 
benefit should be studied more thoroughly. When comparable to motor sleep benefit 
in Parkinson’s disease, this could give more insight in the underlying mechanism. 
Specifically, the dominant hypothesis that dopamine is the mediator of the sleep 
benefit effect could be studied. This hypothesis states that dopamine storages in nigral 
neuronal terminals are replenished during sleep [4, 5, 14]. However, if  sleep benefit 
is also found in diseases with different pathophysiology or objective improvement in 
motor function cannot be found (either in Parkinson’s disease or other diseases), this 
hypothesis would be less likely.
Qualitative methods in clinical research
The randomised controlled trial is among the most important study designs in 
clinical research. This methodology, based on the positivist framework, is valued for 
its specificity, objectivity and generalizability. However, qualitative research methods, 
adopted from the social sciences, can be a valuable addition to the quantitative 
methodological arsenal [15, 16]. These methods are gaining popularity in for example 
research on quality of care [17-19]. When used correctly they can be of high value, 
especially in an exploratory, hypothesis generating phase of research.
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In our qualitative study we used a grounded theory approach to obtain more insight in 
the subjective patient experiences at waking up (Chapter 6). The extensive interviews 
provided a much more detailed view on the experience of sleep benefit than the 
(quantitative) diary and questionnaires we used before. In hindsight, the qualitative 
study would have been a good starting point for the research on sleep benefit. 
Had we had a better idea of the phenomenology of sleep benefit at the outset, we 
probably would have made different choices.  For example, we might have organized 
the definition and inclusion of patients with and without sleep benefit differently, and 
this issue should be an import point of attention in future research. Specifically, we 
now know that the group of patients reporting sleep benefit in a questionnaire is 
very heterogeneous. A more careful selection of subjects, for example based on an 
interview, will be needed to study more representative groups.
Clinical implications
When we started our research on sleep benefit, we imagined great clinical potential 
for sleep benefit. In our review we speculated on options such as; treatment delivered 
as scheduled afternoon naps as an addition to regular dopaminergic  therapy, or 
medically improved night sleep to enhance morning effects (Chapter 3).  However, 
in chapter 5 we assessed sleep related changes in motor function using quantitative 
motor tasks. We were not able to show objective effects of sleep benefit; we found 
no improvement in Parkinson symptoms after sleep. Based on this study, there is no 
motive to routinely promote sleep benefit in the clinic. Nevertheless, there are patients 
who report a clear beneficial effect of sleep (Chapter 7). There is obviously no reason 
to discourage these patients to take an afternoon nap if they feel better afterwards, 
regardless whether this effect is subjective or objective .  
Future research
In chapter 7 we presented a research proposal for a future study on sleep benefit. We 
introduced a new technique for computerized vision based (video) analyses that can 
be used to assess motor performance upon awakening in a home environment. This 
technique has several advantages:  It allows for objective and accurate assessment of 
motor performance  in the patient’s home situation where it can be used easily for lon-
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gitudinal assessment.  It is possible to quantify spontaneous movements and normal/
daily movement patterns, without subjects having to wear sensors or perform “tests”.
The possibility to asses spontaneous functioning, without the use of motor tasks is 
a great advantage of this study. In a quantitative motor task patients receive cues to 
perform certain behaviour. Many Parkinson’s patients benefit from cues to start or 
maintain movement [20, 21]. So, the motor performance in a quantified motor task 
might not be representative for spontaneous movement. Furthermore, in chapter 6 
we noticed that many patients reported stress related factors to be of great influence 
on their symptoms. We hypothesized that the motor tasks that had to be performed 
at awakening in the study in chapter 5 might have been consciously or unconsciously 
stressful for the patients, this could have contributed to the negative findings in this 
study. We expect that patients will get used to the presence of a camera in their bedroom 
quickly and over time possibly even forget that it is there. The more comfortable the 
patients feel, the more natural and representative their morning functioning will be.
With advancing technology, the integration of sensors and intelligent devices in the 
home environment becomes more popular. The (research on) applications in elderly 
care and home rehabilitation are growing [22-25]. However, techniques like these also 
come with questions on security and privacy [26-28]. In a questionnaire on activities 
in the home that subjects would not want recorded, most mentioned activities were 
related to self-appearance (nudity, walking in underwear, no makeup) and intimacy 
[26]. These are typically activities that are associated with the bedroom. Therefore, we 
chose to only record during the specific timeframe of awakening and getting out of 
bed, in our study proposal (Chapter 7). Furthermore, patients have full control over 
the video system. After completing the study we will debrief patients thoroughly about 
their experience with the system and privacy related issues. This will provide valuable 
information for further development of vision based techniques for home monitoring.
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Some patients with Parkinson’s disease experience a beneficial effect of sleep. They 
report improved mobility upon awakening, contrary to what would be expected after 
a night without medication. This interesting phenomenon is known as ‘sleep benefit’. 
In this thesis sleep benefit was studied and described from several perspectives, and 
employing diverse methodology.
Chapter 2 presents the results of our first questionnaire study on sleep benefit. In 
a cohort of 243 Parkinson’s patients, 46.9% of patients reported to be familiar with 
sleep benefit. Among those patients who regularly took a nap, 33.7% experienced 
sleep benefit after a nap as well. We found no differences in clinical or demographic 
characteristics between patients with and without subjective sleep benefit. However, 
the high self-reported prevalence of sleep benefit was reason to renew the research 
on this intriguing phenomenon.
In chapter 3 we performed a systematic review of the literature on sleep benefit. 
Most studies used questionnaires to study sleep benefit. There was large variation 
in the characteristics of sleep benefit found in different studies. Only one study used 
objective measures (UPDRS III) to assess sleep benefit. Across studies we found 
large variation in the definition of sleep benefit. This could in part explain the different 
findings across studies. Therefore, we proposed to combine these definition into 
one general definition for sleep benefit: sleep benefit is the experience of a temporary 
decrease in Parkinson’s symptoms upon awakening after a period of sleep (night or 
daytime), before drug intake; the patient is feeling as good as “on” (or better).
Several hypotheses for the underlying mechanism of sleep benefit were discussed. 
Sleep benefit could be caused by replenishment of dopamine in nigral neuronal 
terminals during sleep. Others proposed that sleep benefit is merely a morning benefit, 
related to diurnal motor fluctuations rather than an effect of sleep. Even a beneficial 
effect of sleep deprivation was suggested, however, this hypothesis seemed less likely.
Sleep benefit could have great clinical potential, for example in scheduled afternoon 
naps as an addition to regular dopaminergic therapy. However, more research on the 
(objective) effects of sleep benefit is needed. 
Chapter 4 studied sleep benefit prospectively using a 7-day symptom diary. Patients 
completed this diary at bedtime and directly at awakening. They gave an indication 
of their motor abilities at that specific moment. A positive change in motor function 
was observed after 267 nights (17.8%) and after 138 daytime naps (23.4%). Based on 
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these results, 75 patients (32%) were classified as having sleep benefit. In response to 
a subsequent retrospective questionnaire, 73 patients (31%) reported to experience 
sleep benefit. Interestingly, the groups with sleep benefit according to either the diary 
or the questionnaire overlapped only partially: outcomes were congruent in 63% of 
subjects (both negative 49%, both positive 14%). The subjective experience of sleep 
benefit was not always related to an actual increase in reported motor function. This 
showed the need for objective measures of sleep benefit.
Chapter 5 assessed sleep related changes in motor function using quantitative motor 
tasks. 18 Parkinson’s patients with and 20 without subjective sleep benefit and 20 
healthy controls participated. The tasks were performed before and after night sleep 
and a daytime nap. On both the pegboard task and the finger tapping tasks, patients 
were overall slower than healthy controls (night: F2,55 = 16.938, p = 0.000; nap: F2,55 
= 15.331, p = 0.000). On the pegboard task, there was a small main effect of night 
sleep (F1,55 = 9.695, p = 0.003); both patients and controls were on average slightly 
slower in the morning. However, on both tasks there was no sleep*group interaction, 
neither for nighttime sleep nor for the afternoon nap. We found no correlations in task 
performance and mood/vigilance or sleep time/efficiency. 
This study showed that the subjective experience of sleep benefit is not accompanied 
by an actual improvement in motor functioning. Sleep benefit appeared to be a sub-
jective phenomenon rather than a Parkinson-specific reduction in symptoms.
In chapter 6 we used a grounded theory approach to get more insight in what patients, 
who report sleep benefit, experience when they wake up. We interview 14 patients 
that unambiguously reported subjective sleep benefit in a questionnaire. Some, but 
certainly not all, patients described a temporal decrease in their Parkinson motor 
symptoms after sleep. However, several patients did not meet the definition of sleep 
benefit at all. Others experienced beneficial effects of sleep, but not a specific decrease 
of motor symptoms. There were no general sleep related factors that influenced the 
presence of sleep benefit. Other factors that were mentioned to influence functioning 
at awakening were mostly stress related.
This study showed that the group of patients convincingly reporting sleep benefit in a 
questionnaire was very heterogeneous, with only a portion of the patients describing 
motor sleep benefit. Probably the group of patients actually experiencing motor sleep 
benefit is far smaller than thought so far, based on previous questionnaire studies.
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In chapter 7 we presented a study design for future research on sleep benefit. We 
introduced a new technique for computerized vision based (video) analyses that can 
be used to assess motor performance upon awakening in a home environment. 30 
Parkinson’s patients (15 with and 15 without subjective sleep benefit), will have a video 
camera installed in their bedroom during a 4 week follow-up period. The camera will 
record from one hour before until one hour after awakening and register te morning ritual 
including walking from te bed to the bedroom door. With this technique spatiotemporal 
and kinematic data (such as walking speed, joint angles, step length, arm swing etc) 
can be automatically extracted from the video registration. This allows for longitudinal 
objective assessment of daily life movements without having to wear sensors.
In chapter 8 the main findings of this thesis were discussed. We addressed recurring 
themes in the different studies, such as the definition of sleep benefit and whether it 
is a subjective or objective phenomenon. Furthermore,  directions and challenges for 
future research were evaluated, with a focus on the role of qualitative and computer 
vision methods in clinical research.
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Sommige patiënten met de ziekte van Parkinson ervaren een gunstig effect van slapen. 
Bij het wakker worden kunnen ze makkelijker bewegen, in tegenstelling wat je zou 
verwachten na een hele nacht zonder medicatie. Dit fenomeen wordt “sleep benefit” 
genoemd. In dit proefschrift bestudeerden en beschreven we sleep benefit vanuit 
verschillende perspectieven, gebruikmakend van diverse onderzoeksmethoden.
In hoofdstuk 2 presenteerden we de resultaten van onze eerste vragenlijststudie naar 
sleep benefit. In een cohort van 243 Parkinson patiënten had 46,9% van de patiënten 
ervaring met de gunstige effecten van slaap. Van de patiënten die regelmatig een 
middagdutje deden, had 33,7% ook na het dutje sleep benefit. We vonden geen 
klinische en demografische verschillen tussen de patiënten met en zonder subjectieve 
sleep benefit. Het hoge percentage patiënten dat bekend was met sleep benefit, was 
reden om het onderzoek naar dit interessante fenomeen weer nieuw leven in te blazen.
In hoofdstuk 3 gaven we een systematisch overzicht van de literatuur over sleep ben-
efit. De meeste onderzoeken gebruikten vragenlijsten om sleep benefit te bestuderen. 
Er waren grote verschillen in de gevonden kenmerken van sleep benefit. Er was maar 
één studie die objectieve maten (UPDRS III) gebruikte.
In de verschillende onderzoeken vonden we grote variatie in de definitie van sleep 
benefit. Dit kan gedeeltelijk de verschillen in de gevonden kenmerken van sleep benefit 
verklaren. Daarom hebben we alle definities gecombineerd tot een nieuwe definitie: 
Na een periode van slaap (nachtslaap of een middagdutje), voor de inname 
van de Parkinsonmedicatie ervaart de patiënt een tijdelijke afname van 
de Parkinson symptomen; de patiënt voelt zich net zo goed als wanneer de 
Parkinsonmedicatie werkt (of beter).
We bespraken verschillende hypotheses voor het onderliggende mechanisme 
van sleep benefit. De verbetering kan veroorzaakt worden door een aanvulling van 
dopamine in de neuronen van de substantia nigra tijdens slaap. Anderen denken 
dat de verbetering worden veroorzaakt door circadiane verschillen in functioneren, 
dus door het moment van de dag in plaats van de voorafgaande periode van slaap. 
Er werd zelfs gesproken over de positieve effecten van slaaponthouding, maar deze 
hypothese leek minder waarschijnlijk.
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Sleep benefit zou interessante klinische toepassingen kunnen hebben, bijvoorbeeld 
in de vorm van een gepland middagdutje, als aanvulling op de reguliere dopaminerge 
medicatie. Daarvoor moet eerst meer onderzoek gedaan worden naar de (objectieve) 
effecten sleep benefit.
In hoofdstuk 4 gebruikten we een symptomendagboek om sleep benefit gedurende 
7 dagen prospectief te onderzoeken. De patiënten vulden dit dagboek in bij het 
naar bed gaan en direct bij het wakker worden, daarbij gaven ze een cijfer voor de 
motorische symptomen op dat moment. Na 267 nachten (17,8%) en 138 middagdutjes 
(23,4%) vonden we een verbetering in het motorisch functioneren. 75 patiënten (32%) 
hadden sleep benefit op basis van deze gegevens. In de daaropvolgende vragenlijst 
gaven 73 patiënten (31%) aan dat zij sleep benefit ervaren. Echter, de groepen met 
sleep benefit overlapten maar gedeeltelijk; in 63% van de gevallen kwamen beide 
instrumenten overeen (49% beide geen sleep benefit, 14% beide wel sleep benefit). 
De ervaring van sleep benefit ging niet altijd gepaard met een verbetering in de 
beoordeling van de motorische symptomen. Daarom zijn objectieve maten om sleep 
benefit te kunnen meten hard nodig. 
Hoofdstuk 5 bestudeerde slaapgerelateerde veranderingen in het motorisch functio- 
neren met behulp van kwantitatieve taken voor de motoriek. 18 Parkinson patiënten 
met en 20 patiënten zonder sleep benefit deden mee,  en daarnaast nog 20 gezon-
de controle personen. De taken werden uitgevoerd voor en na de nachtrust en een 
middagdutje. Op zowel de pegboard taak als de fingertapping taak waren de patiën-
ten langzamer dan de controles (nacht: F2,55 = 16.938, p = 0.000; dutje: F2,55 = 15.331, 
p = 0.000). Op de pegboard taak vonden we een klein effect van de nachtrust (F1,55 
= 9.695, p = 0.003); zowel patiënten als controles waren ’s ochtends iets langzamer. 
Echter, voor beide taken vonden we geen slaap*groep interactie, zowel bij de nacht-
rust als het middagdutje. We vonden ook geen correlatie tussen de scores op de taken 
en gemoedstoestand/alertheid of slaapduur/-efficiëntie. 
Deze studie liet zien dat de subjectieve ervaring van sleep benefit niet gepaard gaat 
met een objectieve verbetering in het motorisch functioneren. Sleep benefit is moge-
lijk een subjectief fenomeen in plaats van een Parkinson-specifieke verbetering van 
de motorische symptomen.
In hoofdstuk 6 gebruikten we het grounded theory framework om meer inzicht te 
krijgen in wat patiënten die sleep benefit rapporteren, ervaren als ze wakker worden. 
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We interviewden 14 patiënten die in een vragenlijst duidelijk aangaven subjectieve 
sleep benefit te ervaren. Een aantal, maar zeker niet alle, patiënten beschreven een 
afname van de Parkinson symptomen bij het wakker worden. Er waren echter ook 
patiënten die helemaal niet voldeden aan de definitie van sleep benefit. Weer anderen 
merkten wel een positief effect van slaap, maar geen specifieke verbetering in het 
motorisch functioneren. Er waren geen algemene slaapgerelateerde factoren die de 
aanwezigheid van sleep benefit beïnvloedde. Andere factoren die invloed hadden op 
het functioneren bij het wakker worden waren vooral stress gerelateerd. 
Deze studie liet zien dat de patiënten die in een vragenlijst overtuigend aangaven sleep 
benefit te ervaren, een hele heterogene groep vormen. Slechts een deel beschreef 
daadwerkelijk een verbetering in het motorisch functioneren. Waarschijnlijk is de 
groep die echt motorische sleep benefit ervaart veel kleiner dan tot u toe gedacht 
werd op basis van vragenlijsten.
In hoofdstuk 7 presenteerden we een onderzoeksprotocol voor toekomstig onderzoek 
naar sleep benefit. We introduceerden een nieuwe techniek op basis van computer 
vision, voor het analyseren van videobeelden. Met behulp van deze techniek kunnen 
we het motorisch functioneren bij het wakker worden bestuderen in de thuissituatie. 
Dertig Parkinsonpatienten (15 met en 15 zonder sleep benefit), zullen gedurende 
4 weken een camera in hun slaapkamer krijgen. Deze camera zal opnemen vanaf 
1 uur voor het wakker worden tot 1 uur na het wakker worden. Op deze manier wordt 
het functioneren in de ochtend vast gelegd, inclusief het lopen van het bed naar de 
slaperkamerdeur. Spatio-temporele en kinematische gegevens (zoals loopsnelheid, 
stapgrote, armzwaai enz.) kunnen vervolgens automatisch uit de videobeelden 
afgeleid worden. Hiermee is het mogelijk om over een langere periode de dagelijkse 
bewegingen te analyseren zonder dat de patiënt sensoren hoeft te dragen.
Hoofdstuk 8 was een discussie van de belangrijkste resultaten van dit proefschrift. 
Thema’s die in de verschillende studies terug kwamen, zoals de definitie van sleep 
benefit en het subjectieve/objectieve karakter van het fenomeen, werden besproken. 
Daarnaast was er ook aandacht voor toekomstig onderzoek, met de focus op de 
toepassing van kwalitatieve onderzoeksmethoden en computer vision-technieken in 
klinisch onderzoek.
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Dankwoord
Ik heb de afgelopen jaren met veel plezier gewerkt aan dit proefschrift. Dankzij de bij-
dragen en hulp van velen anderen is het een boekje geworden waar ik trots op ben. 
Een aantal mensen wil ik in het bijzonder bedanken:
Allereerst alle patiënten en vrijwilligers die hebben deelgenomen aan de verschillende 
onderzoeken. Zonder data geen wetenschap; alle deelnemers hartelijk dank voor jullie 
inzet en enthousiasme! 
Daarna volgt natuurlijk Sebas. Toen jij de VIDI kreeg voor het sleep benefit onderzoek 
lag er eigenlijk al een compleet plan op tafel. Toch heb je mij de afgelopen jaren alle 
ruimte gegeven om er ook echt mijn project van te maken. Dat resulteerde soms in 
fanatieke discussies, maar toen jij in het eerste jaar van een van die meningsverschil-
len een weddenschap maakte, wist ik dat met jou goed zaken te doen is. (De wijn was 
trouwens heerlijk!) Je hebt me altijd uitgedaagd om het beste uit mezelf te halen en op 
mijn eigen ideeën te vertrouwen. Ik heb veel van je geleerd, bedankt voor de fijne en 
inspirerende samenwerking!
Bas, bedank voor je onuitputtelijke enthousiasme en aanstekelijke liefde voor het vak. 
Zelfs als alles tegen leek te zitten wist jij er wel weer een positieve draai aan te geven. 
Jouw klinische expertise en uitgebreide onderzoekservaring hebben mijn onderzoek 
naar een hoger niveau gebracht.
Een deel van mijn onderzoek is uitgevoerd op slaapcentrum Kempenhaeghe. Ik ben 
daar geweldig geholpen door de slaapverpleegkundigen en laboranten. Jullie heb-
ben mij een hoop werk uit handen genomen en met z’n allen hebben we in recordtijd 
een enorm aantal patiënten kunnen meten. 
Petra, de eerste keer dat jij je hulp aanbood reageerde ik wat aarzelend, maar zonder 
jou was het niet gelukt om dit project uit te voeren. Je regelde van alles achter de 
schermen, maar je stond ook elke week om 6 uur ’s ochtends klaar om mee testen 
uit te voeren zodra de deelnemers wakker werden. Zo vroeg was ik meestal nog niet 
zo spraakzaam, maar de rest van de dag was het vooral ook heel gezellig om met jou 
samen te werken!
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Marjan, jouw ervaring op het gebied van kwalitatief onderzoek was onmisbaar voor de 
interviewstudie. Door jou ben ik ook gaan geloven in deze onderzoeksmethode, nu de 
rest van de wereld nog! 
Iris, jij hebt tijdens je stage een indrukwekkende hoeveelheid werk verzet. Ik vond het 
heel leuk om samen de bijzondere verhalen van patiënten te analyseren.
Broni en Nienke, ik ben heel trots dat jullie verder gaan met het onderzoek naar sleep 
benefit en de video-analysestudie uitgewerkt hebben. Ik kan niet wachten op de eer-
ste resultaten en de leuke verdere samenwerking!
Op mijn kamer op de KNF heb ik door de jaren heen heel wat kamergenoten versle-
ten. Pauline, Loes, Renate, Noortje, Susanne, Margot, Saskia, Willemijn, Femke, Kar-
lien, Michiel, Anke, Tim, Nienke en Elske; Een bonte mix van onderzoekers en artsen, 
met een nog gevarieerdere mengelmoes van onderzoeksgebieden. Dat was niet al-
leen heel leerzaam, maar vooral heel gezellig! Met z’n allen hebben we hard gewerkt 
voor de wetenschap, maar ook liters koffie gedronken en uren volgekletst. Allemaal 
bedankt voor de gezelligheid, wetenschappelijke discussies, goede raad, wie is de 
mol?-analyses, taart, klinische lessen, wandelingen en opbeurende woorden als het 
even tegen zat. Ik ga straks gelijk mijn boekenlegger op de deur hangen!
Maartje, jij bent nooit kamergenoot geweest, maar misschien wel mijn meest directe 
collega. In elk geval de enige die zich met hetzelfde onderwerp bezighield. Toen ik 
begon heb jij me ingewijd in de wondere wereld van het slaaponderzoek. Toen jij al 
klaar was zagen we elkaar vooral op symposia en congressen. Door jouw gezelschap 
veranderden die van werkbezoeken in gezellige uitjes. 
Lieve Fred, jou vragen als paranimf was geen moeilijke keuze. Niet alleen kennen we 
elkaar al ons halve leven, ook deden wij op de middelbare school al samen een onder-
zoek(je) naar de effecten van slaapdeprivatie. De jaren erna woonden we in verschillen-
de steden, maar er waren heel veel etentjes, vakanties, feestjes en eindeloze telefoon-
gesprekken. Met jou raak ik nooit uitgepraat. We hebben al zo veel samen meegemaakt 
dat het bijna vanzelfsprekend is dat je ook bij mijn promotie naast me staat.  
Femke, jij bent mijn paranimf, kamergenoot-voor-een-dag-in-de-week, mede-trein-
reiziger naar Utrecht, maar vooral een lieve collega. Ondanks ons totaal verschillende 
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onderzoeksgebied, hebben we heel wat onderzoeksfrustraties en –triomfen gedeeld. 
Door jouw oprechte interesse in mensen kon ik ook altijd mijn hart luchten over per-
soonlijke zaken, dat waren altijd fijne gesprekken. De nachtelijke autoritten die we sa-
men maakten waren iets minder succesvol, maar gelukkig zijn we altijd veilig thuis 
gekomen.
Lieve vrienden, (schoon)familie en collega’s, bedankt dat jullie er waren toen ik het 
zo hard nodig had. Jullie hartverwarmende steun heeft er voor gezorgd dat ik weer 
energie kreeg om verder te gaan met dingen die ineens minder belangrijk leken (zo-
als het schrijven van een proefschrift). Maar niet alleen in verdrietige tijden kon ik op 
jullie rekenen, ik denk ook aan alle leuke en gezellige momenten die het leven van een 
promovendus nog aangenamer maken. Heel erg bedankt!
Lieve vriendinnen, met jullie deel ik al (meer dan) 10 jaar (!) lief en leed, jullie verdienen 
een speciale plek. Maaike, dankzij jou blijf ik zowel fysiek als mentaal in shape. Onze 
sportieve prestaties en uitgebreide analyses van belangrijke en minder belangrijke 
zaken zijn al jaren een constante en onmisbare factor. Lieke, voor mijn portie cultuur 
en (twee)wekelijkse bijklets-maaltijd kan ik altijd bij jou terecht. Ik hoop dat we dit nog 
tot in lengte van dagen vol blijven houden! Puck en Annemieke, wie zou ik anders zo 
gek krijgen om mee naar Rusland te fietsen, gewoon omdat het een leuke uitdaging 
is? Ook al wonen jullie straks ver en heel ver weg, we blijven dit soort plannen maken 
(en uitvoeren!). Linde, bij jou was het altijd gezellig thuiskomen. Nu heb je je eigen 
huisje, maar samen lekker eten en kletsen over neuroscience kan gelukkig nog steeds. 
Noor, jij verhuist ook steeds verder bij mij vandaan, maar met onze (te schaarse) tele-
foongesprekken ben je weer heel dichtbij.
Koos en Margriet,  Jan en Ingrid, Pieter en Karla,  Judith en Oege, bedankt voor alle 
koffiepauzes (Karla), dierenkaarten (Margriet), Parijs-tripjes (Oege) en troostrijke eten-
tjes (allemaal). En vooral bedankt dat jullie er waren op alle belangrijke en moeilijke 
momenten van de afgelopen tijd.
Lieve Juul, zoals met alles heb jij me ook bij mijn promotieonderzoek van uitgebreid 
advies voorzien. Jij zocht de beste laptops voor mijn experimenten of vliegtickets voor 
een congresbezoek. Ik wou dat ik jou ook op de of andere manier had kunnen helpen. 
Ik weet zeker dat jij net zo hebt genoten van onze broer-zus etentjes en stedentripjes 
als ik, hopelijk heeft dat je wat welkome afleiding bezorgd. Ik mis je!
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Lieve papa en mama, jullie hebben mij altijd gestimuleerd om mijn eigen keuzes te 
maken. Na wat omzwervingen via oa kunstmatige intelligentie promoveer ik nu toch 
“gewoon” in de medische wetenschappen. Dat is ook niet erg verwonderlijk met jullie 
als ouders, wetenschap en gezondheidszorg zijn me met de paplepel ingegoten. Nu 
ik werk in een wereld die jullie zo goed kennen, is het nog leuker om over mijn werk te 
vertellen en ervaringen uit te wisselen.
De afgelopen tijd is niet makkelijk geweest. We doen het allemaal op onze eigen 
manier, maar ook samen. Ik zeg het niet vaak, maar ik hou heel veel van jullie.
Lieve Tom, we leerden elkaar kennen in de meest heftige tijd van mijn leven en jij was 
er voor me, dag en nacht. Inmiddels hebben we al veel verdrietige, maar ook heel 
veel mooie dingen samen meegemaakt. Met jou kan ik praten en zwijgen, lachen en 
huilen, soms allemaal tegelijk. Jij bent mijn rots in de branding, bij jou ben ik thuis. 
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